Annotation
literal: BFO 2 Reference: BFO does not claim to provide complete coverage of entities of all types. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning - coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation.

Annotation
literal: BFO 2 Reference: BFO's treatment of continuants and occurrents - as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality - earlier called the 'SNAP' and 'SPAN' perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science.

Annotation
literal: BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. 'Entity' is an example of a primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms.

Annotation
literal: Alan Ruttenberg

Annotation
literal: Albert Goldfain

Annotation
literal: Asiyah Yu Lin (CDRH, Food and Drug Administration)

Annotation
literal: Astghik Sargsyan (Fraunhofer SCAI)

Annotation
literal: Barry Smith

Annotation
literal: Bill Duncan

Annotation
literal: Bjoern Peters

Annotation
literal: Chris Mungall

Annotation
literal: David Osumi-Sutherland

Annotation
literal: Fabian Neuhaus

Annotation
literal: Geena Mariya Jose (Causality Biomodels)

Annotation
literal: Holger Stenzhorn

Annotation
literal: James A. Overton

Annotation
literal: Janna Hastings

Annotation
literal: Jie Zheng

Annotation
literal: Jonathan Bona

Annotation
literal: Larry Hunter

Annotation
literal: Leon Li (NIH)

Annotation
literal: Leonard Jacuzzo

Annotation
literal: Ludger Jansen

Annotation
literal: Mark Ressler

Annotation
literal: Mathias Brochhausen

Annotation
literal: Mauricio Almeida

Annotation
literal: Melanie Courtot

Annotation
literal: Oliver He (University of Michigan)

Annotation
literal: Pierre Grenon

Annotation
literal: Randall Dipert

Annotation
literal: Ron Rudnicki

Annotation
literal: Selja Seppälä

Annotation
literal: Shounak Baksi (Causality Biomodels)

Annotation
literal: Stefan Schulz

Annotation
literal: Thomas Bittner

Annotation
literal: Werner Ceusters

Annotation
literal: Yongqun "Oliver" He

Annotation
literal: The core Ontology of Clinical Trials (CTO) will serve as a structured resource integrating basic terms and concepts in the context of clinical trials. Thereby covering clinicaltrails.gov. CoreCTO will serve as a basic ontology to generate extended versions for specific applications such as annotation of variables in study documents from clinical trials.

Annotation
literal: Alpha Tom Kodamullil (Fraunhofer SCAI)

Annotation
literal: Johannes Darms (Fraunhofer SCAI)

Annotation
literal: Stephan Gebel (Fraunhofer SCAI)

Annotation
literal: Sumit Madan (Fraunhofer SCAI)

Annotation
literal: CTO: Core Ontology of Clinical Trials

Annotation
literal: Please see the project site https://github.com/BFO-ontology/BFO, the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel, the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx. This ontology is generated from a specification at https://github.com/BFO-ontology/BFO/tree/master/src/ontology/owl-group/specification/ and with the code that generates the OWL version in https://github.com/BFO-ontology/BFO/tree/master/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif.

Annotation
literal: The BSD license on the BFO project site refers to code used to build BFO.

Annotation
literal: This BFO 2.0 version represents a major update to BFO and is not strictly backwards compatible with BFO 1.1. The previous OWL version of BFO, version 1.1.1 will remain available at http://ifomis.org/bfo/1.1 and will no longer be updated. The BFO 2.0 OWL is a classes-only specification. The incorporation of core relations has been held over for a later version.

Annotation
literal: Version Release: 1.0.0

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
literal: entity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
literal: Entity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
literal: Julius Caesar

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
literal: Verdi’s Requiem

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
literal: the Second World War

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
literal: your body mass index

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
literal: BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000004
annotation:
  literal: per discussion with Barry Smith
annotation:
  IRI: http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf
abbreviated IRI: obo:BFO_0000001
literal: Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/001-001
abbreviated IRI: obo:BFO_0000001
literal: An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000001
literal: entity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: continuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: Continuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000007
abbreviated IRI: obo:BFO_0000002
literal: Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/008-002
abbreviated IRI: obo:BFO_0000002
literal: A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/126-001
abbreviated IRI: obo:BFO_0000002
literal: if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/009-002
abbreviated IRI: obo:BFO_0000002
literal: if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/011-002
abbreviated IRI: obo:BFO_0000002
literal: if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/009-002
abbreviated IRI: obo:BFO_0000002
literal: (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/126-001
abbreviated IRI: obo:BFO_0000002
literal: (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/008-002
abbreviated IRI: obo:BFO_0000002
literal: (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/011-002
abbreviated IRI: obo:BFO_0000002
literal: (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000002
literal: continuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000003
literal: occurrent

AnnotationAssertion
abbreviated IRI: obo:BFO_0000003
literal: Occurrent

AnnotationAssertion
abbreviated IRI: obo:BFO_0000003
literal: BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000003
literal: BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000006
annotation:
  literal: per discussion with Barry Smith
abbreviated IRI: obo:BFO_0000003
literal: Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000012
abbreviated IRI: obo:BFO_0000003
literal: Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/077-002
abbreviated IRI: obo:BFO_0000003
literal: An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/108-001
abbreviated IRI: obo:BFO_0000003
literal: Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/079-001
abbreviated IRI: obo:BFO_0000003
literal: b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/108-001
abbreviated IRI: obo:BFO_0000003
literal: (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/079-001
abbreviated IRI: obo:BFO_0000003
literal: (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000003
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000003
literal: occurrent

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: ic

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: IndependentContinuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: a chair

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: a heart

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: a leg

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: a molecule

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: a spatial region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: an atom

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: an orchestra.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: an organism

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: the bottom right portion of a human torso

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: the interior of your mouth

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/017-002
abbreviated IRI: obo:BFO_0000004
literal: b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/134-001
abbreviated IRI: obo:BFO_0000004
literal: For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/018-002
abbreviated IRI: obo:BFO_0000004
literal: For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/134-001
abbreviated IRI: obo:BFO_0000004
literal: (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/018-002
abbreviated IRI: obo:BFO_0000004
literal: (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/017-002
abbreviated IRI: obo:BFO_0000004
literal: (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000004
literal: independent continuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000006
literal: s-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000006
literal: SpatialRegion

AnnotationAssertion
abbreviated IRI: obo:BFO_0000006
literal: BFO 2 Reference: Spatial regions do not participate in processes.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000002
annotation:
  literal: per discussion with Barry Smith
abbreviated IRI: obo:BFO_0000006
literal: Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/035-001
abbreviated IRI: obo:BFO_0000006
literal: A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/036-001
abbreviated IRI: obo:BFO_0000006
literal: All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/036-001
abbreviated IRI: obo:BFO_0000006
literal: (forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/035-001
abbreviated IRI: obo:BFO_0000006
literal: (forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000006
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000006
literal: spatial region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000008
literal: t-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000008
literal: TemporalRegion

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000003
annotation:
  literal: per discussion with Barry Smith
abbreviated IRI: obo:BFO_0000008
literal: Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/100-001
abbreviated IRI: obo:BFO_0000008
literal: A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/101-001
abbreviated IRI: obo:BFO_0000008
literal: All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/119-002
abbreviated IRI: obo:BFO_0000008
literal: Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/119-002
abbreviated IRI: obo:BFO_0000008
literal: (forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/101-001
abbreviated IRI: obo:BFO_0000008
literal: (forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/100-001
abbreviated IRI: obo:BFO_0000008
literal: (forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000008
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000008
literal: temporal region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000009
literal: 2d-s-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000009
literal: TwoDimensionalSpatialRegion

AnnotationAssertion
abbreviated IRI: obo:BFO_0000009
literal: an infinitely thin plane in space.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000009
literal: the surface of a sphere-shaped part of space

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/039-001
abbreviated IRI: obo:BFO_0000009
literal: A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/039-001
abbreviated IRI: obo:BFO_0000009
literal: (forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000009
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000009
literal: two-dimensional spatial region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000011
literal: st-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000011
literal: SpatiotemporalRegion

AnnotationAssertion
abbreviated IRI: obo:BFO_0000011
literal: the spatiotemporal region occupied by a human life

AnnotationAssertion
abbreviated IRI: obo:BFO_0000011
literal: the spatiotemporal region occupied by a process of cellular meiosis.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000011
literal: the spatiotemporal region occupied by the development of a cancer tumor

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/095-001
abbreviated IRI: obo:BFO_0000011
literal: A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/096-001
abbreviated IRI: obo:BFO_0000011
literal: All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/099-001
abbreviated IRI: obo:BFO_0000011
literal: Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/098-001
abbreviated IRI: obo:BFO_0000011
literal: Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000011
literal: Every spatiotemporal region occupies_spatiotemporal_region itself.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/107-002
abbreviated IRI: obo:BFO_0000011
literal: Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/107-002
abbreviated IRI: obo:BFO_0000011
literal: (forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/099-001
abbreviated IRI: obo:BFO_0000011
literal: (forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/096-001
abbreviated IRI: obo:BFO_0000011
literal: (forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/095-001
abbreviated IRI: obo:BFO_0000011
literal: (forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/098-001
abbreviated IRI: obo:BFO_0000011
literal: (forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000011
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000011
literal: spatiotemporal region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: process

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: Process

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: a process of cell-division, \ a beating of the heart

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: a process of meiosis

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: a process of sleeping

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: the course of a disease

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: the flight of a bird

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: the life of an organism

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: your process of aging.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/083-003
abbreviated IRI: obo:BFO_0000015
literal: p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war)

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
abbreviated IRI: obo:ro.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/083-003
abbreviated IRI: obo:BFO_0000015
literal: (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000015
literal: process

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
literal: disposition

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
literal: Disposition

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
literal: an atom of element X has the disposition to decay to an atom of element Y

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
literal: certain people have a predisposition to colon cancer

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
literal: children are innately disposed to categorize objects in certain ways.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
literal: the cell wall is disposed to filter chemicals in endocytosis and exocytosis

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
literal: BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/062-002
abbreviated IRI: obo:BFO_0000016
literal: b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/063-002
abbreviated IRI: obo:BFO_0000016
literal: If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/063-002
abbreviated IRI: obo:BFO_0000016
literal: (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/062-002
abbreviated IRI: obo:BFO_0000016
literal: (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000016
literal: disposition

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: realizable

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: RealizableEntity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: the disposition of this piece of metal to conduct electricity.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: the disposition of your blood to coagulate

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: the function of your reproductive organs

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: the role of being a doctor

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: the role of this boundary to delineate where Utah and Colorado meet

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: A specifically dependent continuant that inheres in continuant entities and are not exhibited in full at every time in which it inheres in an entity or group of entities. The exhibition or actualization of a realizable entity is a particular manifestation, functioning or process that occurs under certain circumstances.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
abbreviated IRI: obo:envo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/058-002
abbreviated IRI: obo:BFO_0000017
literal: To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/060-002
abbreviated IRI: obo:BFO_0000017
literal: All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/060-002
abbreviated IRI: obo:BFO_0000017
literal: (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/058-002
abbreviated IRI: obo:BFO_0000017
literal: (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000017
literal: realizable entity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000018
literal: 0d-s-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000018
literal: ZeroDimensionalSpatialRegion

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/037-001
abbreviated IRI: obo:BFO_0000018
literal: A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/037-001
abbreviated IRI: obo:BFO_0000018
literal: (forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000018
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000018
literal: zero-dimensional spatial region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: quality

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: Quality

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: the ambient temperature of this portion of air

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: the color of a tomato

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: the length of the circumference of your waist

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: the mass of this piece of gold.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: the shape of your nose

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: the shape of your nostril

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/055-001
abbreviated IRI: obo:BFO_0000019
literal: a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/105-001
abbreviated IRI: obo:BFO_0000019
literal: If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/055-001
abbreviated IRI: obo:BFO_0000019
literal: (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/105-001
abbreviated IRI: obo:BFO_0000019
literal: (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000019
literal: quality

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: sdc

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: SpecificallyDependentContinuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: of one-sided specifically dependent continuants: the mass of this tomato

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: the disposition of this fish to decay

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: the function of this heart: to pump blood

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: the mutual dependence of proton donors and acceptors in chemical reactions [79

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: the pink color of a medium rare piece of grilled filet mignon at its center

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: the role of being a doctor

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: the shape of this hole.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: the smell of this portion of mozzarella

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/050-003
abbreviated IRI: obo:BFO_0000020
literal: b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000005
annotation:
  literal: per discussion with Barry Smith
abbreviated IRI: obo:BFO_0000020
literal: Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/050-003
abbreviated IRI: obo:BFO_0000020
literal: (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000020
literal: specifically dependent continuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: role

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: Role

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: the priest role

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: the role of a boundary to demarcate two neighboring administrative territories

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: the role of a building in serving as a military target

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: the role of a stone in marking a property boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: the role of subject in a clinical trial

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: the student role

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: A realizable entity the manifestation of which brings about some result or end that is not essential to a continuant in virtue of the kind of thing that it is but that can be served or participated in by that kind of continuant in some kinds of natural, social or institutional contexts.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/061-001
abbreviated IRI: obo:BFO_0000023
literal: b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/061-001
abbreviated IRI: obo:BFO_0000023
literal: (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000023
literal: role

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: fiat-object-part

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: FiatObjectPart

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: or with divisions drawn by cognitive subjects for practical reasons, such as the division of a cake (before slicing) into (what will become) slices (and thus member parts of an object aggregate). However, this does not mean that fiat object parts are dependent for their existence on divisions or delineations effected by cognitive subjects. If, for example, it is correct to conceive geological layers of the Earth as fiat object parts of the Earth, then even though these layers were first delineated in recent times, still existed long before such delineation and what holds of these layers (for example that the oldest layers are also the lowest layers) did not begin to hold because of our acts of delineation.Treatment of material entity in BFOExamples viewed by some as problematic cases for the trichotomy of fiat object part, object, and object aggregate include: a mussel on (and attached to) a rock, a slime mold, a pizza, a cloud, a galaxy, a railway train with engine and multiple carriages, a clonal stand of quaking aspen, a bacterial community (biofilm), a broken femur. Note that, as Aristotle already clearly recognized, such problematic cases – which lie at or near the penumbra of instances defined by the categories in question – need not invalidate these categories. The existence of grey objects does not prove that there are not objects which are black and objects which are white; the existence of mules does not prove that there are not objects which are donkeys and objects which are horses. It does, however, show that the examples in question need to be addressed carefully in order to show how they can be fitted into the proposed scheme, for example by recognizing additional subdivisions [29

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: the FMA:regional parts of an intact human body.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: the Western hemisphere of the Earth

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: the division of the brain into regions

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: the division of the planet into hemispheres

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: the dorsal and ventral surfaces of the body

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: the upper and lower lobes of the left lung

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: BFO 2 Reference: Most examples of fiat object parts are associated with theoretically drawn divisions

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/027-004
abbreviated IRI: obo:BFO_0000024
literal: b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/027-004
abbreviated IRI: obo:BFO_0000024
literal: (forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000024
literal: fiat object part

AnnotationAssertion
abbreviated IRI: obo:BFO_0000026
literal: 1d-s-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000026
literal: OneDimensionalSpatialRegion

AnnotationAssertion
abbreviated IRI: obo:BFO_0000026
literal: an edge of a cube-shaped portion of space.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/038-001
abbreviated IRI: obo:BFO_0000026
literal: A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/038-001
abbreviated IRI: obo:BFO_0000026
literal: (forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000026
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000026
literal: one-dimensional spatial region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: object-aggregate

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: ObjectAggregate

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: a collection of cells in a blood biobank.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: a swarm of bees is an aggregate of members who are linked together through natural bonds

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: a symphony orchestra

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team)

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: defined by fiat: the aggregate of members of an organization

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: defined through physical attachment: the aggregate of atoms in a lump of granite

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: defined via attributive delimitations such as: the patients in this hospital

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: the aggregate of bearings in a constant velocity axle joint

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: the aggregate of blood cells in your body

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: the nitrogen atoms in the atmosphere

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: the restaurants in Palo Alto

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: your collection of Meissen ceramic plates.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000011
abbreviated IRI: obo:BFO_0000027
literal: An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000301
abbreviated IRI: obo:BFO_0000027
literal: An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee).

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000300
abbreviated IRI: obo:BFO_0000027
literal: ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/025-004
abbreviated IRI: obo:BFO_0000027
literal: b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/025-004
abbreviated IRI: obo:BFO_0000027
literal: (forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000027
literal: object aggregate

AnnotationAssertion
abbreviated IRI: obo:BFO_0000028
literal: 3d-s-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000028
literal: ThreeDimensionalSpatialRegion

AnnotationAssertion
abbreviated IRI: obo:BFO_0000028
literal: a cube-shaped region of space

AnnotationAssertion
abbreviated IRI: obo:BFO_0000028
literal: a sphere-shaped region of space,

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/040-001
abbreviated IRI: obo:BFO_0000028
literal: A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/040-001
abbreviated IRI: obo:BFO_0000028
literal: (forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000028
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000028
literal: three-dimensional spatial region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: site

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: Site

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: Manhattan Canyon)

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: a hole in the interior of a portion of cheese

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: a rabbit hole

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: an air traffic control region defined in the airspace above an airport

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the Grand Canyon

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the Piazza San Marco

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the cockpit of an aircraft

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the hold of a ship

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the interior of a kangaroo pouch

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the interior of the trunk of your car

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the interior of your bedroom

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the interior of your office

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the interior of your refrigerator

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: the lumen of your gut

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: your left nostril (a fiat part – the opening – of your left nasal cavity)

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/034-002
abbreviated IRI: obo:BFO_0000029
literal: b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/034-002
abbreviated IRI: obo:BFO_0000029
literal: (forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000029
literal: site

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: object

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: Object

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: atom

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: cell

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: cells and organisms

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: engineered artifacts

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: grain of sand

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: molecule

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: organelle

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: organism

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: planet

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: solid portions of matter

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: star

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below).

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: BFO 2 Reference: an object is a maximal causally unified material entity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
abbreviated IRI: obo:envo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/024-001
abbreviated IRI: obo:BFO_0000030
literal: b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000030
literal: object

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: gdc

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: GenericallyDependentContinuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: the pdf file on your laptop, the pdf file that is a copy thereof on my laptop

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: A continuant that is dependent on one or other independent continuant bearers. For every instance of A requires some instance of (an independent continuant type) B but which instance of B serves can change from time to time.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/074-001
abbreviated IRI: obo:BFO_0000031
literal: b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/074-001
abbreviated IRI: obo:BFO_0000031
literal: (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000031
literal: generically dependent continuant

AnnotationAssertion
abbreviated IRI: obo:BFO_0000034
literal: function

AnnotationAssertion
abbreviated IRI: obo:BFO_0000034
literal: Function

AnnotationAssertion
abbreviated IRI: obo:BFO_0000034
literal: the function of a hammer to drive in nails

AnnotationAssertion
abbreviated IRI: obo:BFO_0000034
literal: the function of a heart pacemaker to regulate the beating of a heart through electricity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000034
literal: the function of amylase in saliva to break down starch into sugar

AnnotationAssertion
abbreviated IRI: obo:BFO_0000034
literal: BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/064-001
abbreviated IRI: obo:BFO_0000034
literal: A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/064-001
abbreviated IRI: obo:BFO_0000034
literal: (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000034
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000034
literal: function

AnnotationAssertion
abbreviated IRI: obo:BFO_0000035
literal: p-boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000035
literal: ProcessBoundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000035
literal: the boundary between the 2nd and 3rd year of your life.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/084-001
abbreviated IRI: obo:BFO_0000035
literal: p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/085-002
abbreviated IRI: obo:BFO_0000035
literal: Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/085-002
abbreviated IRI: obo:BFO_0000035
literal: (forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/084-001
abbreviated IRI: obo:BFO_0000035
literal: (iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000035
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000035
literal: process boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000038
literal: 1d-t-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000038
literal: OneDimensionalTemporalRegion

AnnotationAssertion
abbreviated IRI: obo:BFO_0000038
literal: the temporal region during which a process occurs.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000038
literal: BFO 2 Reference: A temporal interval is a special kind of one-dimensional temporal region, namely one that is self-connected (is without gaps or breaks).

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/103-001
abbreviated IRI: obo:BFO_0000038
literal: A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/103-001
abbreviated IRI: obo:BFO_0000038
literal: (forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000038
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000038
literal: one-dimensional temporal region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: material

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: MaterialEntity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: a flame

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: a forest fire

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: a human being

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: a hurricane

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: a photon

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: a puff of smoke

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: a sea wave

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: a tornado

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: an aggregate of human beings.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: an energy wave

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: an epidemic

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: the undetached arm of a human being

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: An independent continuant that is spatially extended whose identity is independent of that of other entities and can be maintained through time.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:envo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:ero.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/019-002
abbreviated IRI: obo:BFO_0000040
literal: A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/020-002
abbreviated IRI: obo:BFO_0000040
literal: Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/021-002
abbreviated IRI: obo:BFO_0000040
literal: every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/019-002
abbreviated IRI: obo:BFO_0000040
literal: (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/021-002
abbreviated IRI: obo:BFO_0000040
literal: (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/020-002
abbreviated IRI: obo:BFO_0000040
literal: (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: material entity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000040
literal: material_entity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000051
literal: has part

AnnotationAssertion
abbreviated IRI: obo:BFO_0000055
literal: realizes

AnnotationAssertion
abbreviated IRI: obo:BFO_0000062
literal: preceded by

AnnotationAssertion
abbreviated IRI: obo:BFO_0000062
literal: preceded_by

AnnotationAssertion
abbreviated IRI: obo:BFO_0000140
literal: cf-boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000140
literal: ContinuantFiatBoundary

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/029-001
abbreviated IRI: obo:BFO_0000140
literal: b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000140
literal: BFO 2 Reference: In BFO 1.1 the assumption was made that the external surface of a material entity such as a cell could be treated as if it were a boundary in the mathematical sense. The new document propounds the view that when we talk about external surfaces of material objects in this way then we are talking about something fiat. To be dealt with in a future version: fiat boundaries at different levels of granularity.More generally, the focus in discussion of boundaries in BFO 2.0 is now on fiat boundaries, which means: boundaries for which there is no assumption that they coincide with physical discontinuities. The ontology of boundaries becomes more closely allied with the ontology of regions.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000140
literal: BFO 2 Reference: a continuant fiat boundary is a boundary of some material entity (for example: the plane separating the Northern and Southern hemispheres; the North Pole), or it is a boundary of some immaterial entity (for example of some portion of airspace). Three basic kinds of continuant fiat boundary can be distinguished (together with various combination kinds [29

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000008
abbreviated IRI: obo:BFO_0000140
literal: Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000140
literal: Every continuant fiat boundary is located at some spatial region at every time at which it exists

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/029-001
abbreviated IRI: obo:BFO_0000140
literal: (iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000140
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000140
literal: continuant fiat boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000141
literal: immaterial

AnnotationAssertion
abbreviated IRI: obo:BFO_0000141
literal: ImmaterialEntity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000141
literal: BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10

AnnotationAssertion
abbreviated IRI: obo:BFO_0000141
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000141
literal: immaterial entity

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
literal: 1d-cf-boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
literal: OneDimensionalContinuantFiatBoundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
literal: The Equator

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
literal: all geopolitical boundaries

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
literal: all lines of latitude and longitude

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
literal: the line separating the outer surface of the mucosa of the lower lip from the outer surface of the skin of the chin.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
literal: the median sulcus of your tongue

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/032-001
abbreviated IRI: obo:BFO_0000142
literal: a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/032-001
abbreviated IRI: obo:BFO_0000142
literal: (iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000142
literal: one-dimensional continuant fiat boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000144
literal: process-profile

AnnotationAssertion
abbreviated IRI: obo:BFO_0000144
literal: ProcessProfile

AnnotationAssertion
abbreviated IRI: obo:BFO_0000144
literal: On a somewhat higher level of complexity are what we shall call rate process profiles, which are the targets of selective abstraction focused not on determinate quality magnitudes plotted over time, but rather on certain ratios between these magnitudes and elapsed times. A speed process profile, for example, is represented by a graph plotting against time the ratio of distance covered per unit of time. Since rates may change, and since such changes, too, may have rates of change, we have to deal here with a hierarchy of process profile universals at successive levels

AnnotationAssertion
abbreviated IRI: obo:BFO_0000144
literal: One important sub-family of rate process profiles is illustrated by the beat or frequency profiles of cyclical processes, illustrated by the 60 beats per minute beating process of John’s heart, or the 120 beats per minute drumming process involved in one of John’s performances in a rock band, and so on. Each such process includes what we shall call a beat process profile instance as part, a subtype of rate process profile in which the salient ratio is not distance covered but rather number of beat cycles per unit of time. Each beat process profile instance instantiates the determinable universal beat process profile. But it also instantiates multiple more specialized universals at lower levels of generality, selected from rate process profilebeat process profileregular beat process profile3 bpm beat process profile4 bpm beat process profileirregular beat process profileincreasing beat process profileand so on.In the case of a regular beat process profile, a rate can be assigned in the simplest possible fashion by dividing the number of cycles by the length of the temporal region occupied by the beating process profile as a whole. Irregular process profiles of this sort, for example as identified in the clinic, or in the readings on an aircraft instrument panel, are often of diagnostic significance.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000144
literal: The simplest type of process profiles are what we shall call ‘quality process profiles’, which are the process profiles which serve as the foci of the sort of selective abstraction that is involved when measurements are made of changes in single qualities, as illustrated, for example, by process profiles of mass, temperature, aortic pressure, and so on.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/093-002
abbreviated IRI: obo:BFO_0000144
literal: b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/094-005
abbreviated IRI: obo:BFO_0000144
literal: b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/094-005
abbreviated IRI: obo:BFO_0000144
literal: (forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/093-002
abbreviated IRI: obo:BFO_0000144
literal: (iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000144
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000144
literal: process profile

AnnotationAssertion
abbreviated IRI: obo:BFO_0000145
literal: r-quality

AnnotationAssertion
abbreviated IRI: obo:BFO_0000145
literal: RelationalQuality

AnnotationAssertion
abbreviated IRI: obo:BFO_0000145
literal: John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000145
literal: a marriage bond, an instance of requited love, an obligation between one person and another.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/057-001
abbreviated IRI: obo:BFO_0000145
literal: b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/057-001
abbreviated IRI: obo:BFO_0000145
literal: (iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000145
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000145
literal: relational quality

AnnotationAssertion
abbreviated IRI: obo:BFO_0000146
literal: 2d-cf-boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000146
literal: TwoDimensionalContinuantFiatBoundary

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/033-001
abbreviated IRI: obo:BFO_0000146
literal: a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/033-001
abbreviated IRI: obo:BFO_0000146
literal: (iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000146
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000146
literal: two-dimensional continuant fiat boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000147
literal: 0d-cf-boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000147
literal: ZeroDimensionalContinuantFiatBoundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000147
literal: the geographic North Pole

AnnotationAssertion
abbreviated IRI: obo:BFO_0000147
literal: the point of origin of some spatial coordinate system.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000147
literal: the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/0000001
annotation:
  literal: requested by Melanie Courtot
annotation:
  IRI: https://groups.google.com/d/msg/bfo-owl-devel/s9Uug5QmAws/ZDRnpiIi_TUJ
abbreviated IRI: obo:BFO_0000147
literal: zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona.

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/031-001
abbreviated IRI: obo:BFO_0000147
literal: a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/031-001
abbreviated IRI: obo:BFO_0000147
literal: (iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000147
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000147
literal: zero-dimensional continuant fiat boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: 0d-t-region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: ZeroDimensionalTemporalRegion

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: a temporal region that is occupied by a process boundary

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: right now

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: the moment at which a child is born

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: the moment at which a finger is detached in an industrial accident

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: the moment of death.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: temporal instant.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/102-001
abbreviated IRI: obo:BFO_0000148
literal: A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: (forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001]

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/102-001
abbreviated IRI: obo:BFO_0000148
literal: (forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001]

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000148
literal: zero-dimensional temporal region

AnnotationAssertion
abbreviated IRI: obo:BFO_0000179
literal: BFO OWL specification label

AnnotationAssertion
abbreviated IRI: obo:BFO_0000179
literal: Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification.

AnnotationAssertion
abbreviated IRI: obo:BFO_0000179
literal: Really of interest to developers only

AnnotationAssertion
abbreviated IRI: obo:BFO_0000179
literal: BFO OWL specification label

AnnotationAssertion
abbreviated IRI: obo:BFO_0000179
literal: BFO OWL specification label

AnnotationAssertion
abbreviated IRI: obo:BFO_0000180
literal: BFO CLIF specification label

AnnotationAssertion
abbreviated IRI: obo:BFO_0000180
literal: Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2

AnnotationAssertion
abbreviated IRI: obo:BFO_0000180
literal: Person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:BFO_0000180
literal: Really of interest to developers only

AnnotationAssertion
abbreviated IRI: obo:BFO_0000180
literal: BFO CLIF specification label

AnnotationAssertion
abbreviated IRI: obo:BFO_0000180
literal: BFO CLIF specification label

AnnotationAssertion
abbreviated IRI: obo:BFO_0000182
literal: history

AnnotationAssertion
abbreviated IRI: obo:BFO_0000182
literal: History

AnnotationAssertion
annotation:
  IRI: http://purl.obolibrary.org/obo/bfo/axiom/138-001
abbreviated IRI: obo:BFO_0000182
literal: A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001])

AnnotationAssertion
abbreviated IRI: obo:BFO_0000182
abbreviated IRI: obo:bfo.owl

AnnotationAssertion
abbreviated IRI: obo:BFO_0000182
literal: history

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: molecular entity

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity.

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: We are assuming that every molecular entity has to be completely connected by chemical bonds. This excludes protein complexes, which are comprised of minimally two separate molecular entities. We will follow up with Chebi to ensure this is their understanding as well

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
abbreviated IRI: obo:chebi.owl

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: molecular entity

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: chebi_ontology

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: entidad molecular

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: entidades moleculares

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: entite moleculaire

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: molecular entities

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: molekulare Entitaet

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: CHEBI:23367

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/chebi#3_STAR

AnnotationAssertion
abbreviated IRI: obo:CHEBI_23367
literal: molecular entity

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
literal: A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances.

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
abbreviated IRI: obo:chebi.owl

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
literal: chemical entity

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
literal: chebi_ontology

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
literal: CHEBI:24431

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/chebi#3_STAR

AnnotationAssertion
abbreviated IRI: obo:CHEBI_24431
literal: chemical entity

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000001
literal: An identifier(s) (ID), if any, other than the organization's Unique Protocol Identification Number or the NCT number that is assigned to the clinical study. This includes any unique clinical study identifiers assigned by other publicly available clinical trial registries. If the clinical study is funded in whole or in part by a U.S. Federal Government agency, the complete grant or contract number must be submitted as a Secondary ID.

AnnotationAssertion
annotation:
  literal: https://www.who.int/ictrp/network/trds/en/
abbreviated IRI: obo:CTO_0000001
literal: Other identifiers besides the Trial Identifying Number allocated by the Primary Registry, if any.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000001
literal: secondary identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000002
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Australian New Zealand clinical trials registry (ANZCTR). The format for the registry number is “ACTRN” followed by a 14-digit number, e.g., ACTRN12620000457943.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000002
literal: ANZCTR identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000002
literal: Australian New Zealand clinical trials registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000002
literal: http://www.anzctr.org.au/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000002
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000003
literal: Australian New Zealand Clinical Trials Registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000003
literal: ANZCTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000003
literal: Australian New Zealand clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000003
literal: http://www.anzctr.org.au/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000003
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000004
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Peruvian clinical trial registry (REPEC). The format for the registry number is “PER-” followed by a 3-digit number, followed by a hyphen, followed by a 2-digit number e.g., PER-010-20.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000004
literal: REPEC identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000004
literal: Peruvian clinical trial registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000004
literal: https://ensayosclinicos-repec.ins.gob.pe/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000004
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000005
literal: The party or parties involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000005
literal: blinding

AnnotationAssertion
abbreviated IRI: obo:CTO_0000005
literal: masking

AnnotationAssertion
abbreviated IRI: obo:CTO_0000005
literal: masking design

AnnotationAssertion
abbreviated IRI: obo:CTO_0000005
literal: http://www.icmje.org/recommendations/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000005
literal: http://www.who.int/ictrp/network/trds/en/index.html

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000006
literal: Participants are expressly assigned to intervention groups through a non-random method, such as physician choice

AnnotationAssertion
abbreviated IRI: obo:CTO_0000006
literal: non-randomized

AnnotationAssertion
abbreviated IRI: obo:CTO_0000006
literal: nonrandomized

AnnotationAssertion
abbreviated IRI: obo:CTO_0000006
literal: non-random allocation

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:CTO_0000007
literal: A study record that includes the summary results posted in the ClinicalTrials.gov results database. Summary results information includes participant flow, baseline characteristics, outcome measures, and adverse events (including serious adverse events).

AnnotationAssertion
abbreviated IRI: obo:CTO_0000007
literal: summary results

AnnotationAssertion
abbreviated IRI: obo:CTO_0000007
literal: study summary result

AnnotationAssertion
abbreviated IRI: obo:CTO_0000007
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000008
literal: A description of each secondary outcome measure (or for observational studies, specific secondary measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment). Each secondary outcome measure information includes title, description and time frame.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000008
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
annotation:
  literal: https://www.who.int/ictrp/network/trds/en/
abbreviated IRI: obo:CTO_0000008
literal: key secondary outcome

AnnotationAssertion
abbreviated IRI: obo:CTO_0000008
literal: secondary outcome measure information

AnnotationAssertion
abbreviated IRI: obo:CTO_0000008
literal: https://clinicaltrials.gov/ct2/about-studies/glossary

AnnotationAssertion
abbreviated IRI: obo:CTO_0000009
literal: The Iranian registry of clinical trials is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000009
literal: IRCT

AnnotationAssertion
abbreviated IRI: obo:CTO_0000009
literal: Iranian registry of clinical trials

AnnotationAssertion
abbreviated IRI: obo:CTO_0000009
literal: http://www.irct.ir/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000009
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000010
literal: Any other measurements, excluding post-hoc measures, that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. Each primary outcome measure information includes title, description and time frame.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000010
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000010
literal: other pre-specified outcome measures

AnnotationAssertion
abbreviated IRI: obo:CTO_0000010
literal: other outcome measure information

AnnotationAssertion
abbreviated IRI: obo:CTO_0000011
literal: The Indian clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000011
literal: CTRI

AnnotationAssertion
abbreviated IRI: obo:CTO_0000011
literal: clinical trials registry - India

AnnotationAssertion
abbreviated IRI: obo:CTO_0000011
literal: Indian clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000011
literal: http://ctri.nic.in/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000011
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000012
literal: The Netherlands national trial register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000012
literal: NTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000012
literal: The Netherlands national trial register

AnnotationAssertion
abbreviated IRI: obo:CTO_0000012
literal: http://www.trialregister.nl/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000012
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000013
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Iranian registry of clinical trials (IRCT). The format for the registry number is “IRCT” followed by a 14-digit number, one letter and again one or two numbers, e.g., IRCT20100228003449N29.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000013
literal: IRCT identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000013
literal: Iranian registry of clinical trials identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000013
literal: http://www.irct.ir/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000013
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000014
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the German clinical trials register (DRKS). The format for the registry number is “DRKS” followed by a 8-digit number, e.g., DRKS00000494.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000014
literal: DRKS identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000014
literal: German clinical trials register identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000014
literal: https://www.drks.de/drks_web/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000014
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000015
literal: The Cuban public registry of clinical trials is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000015
literal: RPCEC

AnnotationAssertion
abbreviated IRI: obo:CTO_0000015
literal: Cuban public registry of clinical trials

AnnotationAssertion
abbreviated IRI: obo:CTO_0000015
literal: http://registroclinico.sld.cu/en/home

AnnotationAssertion
abbreviated IRI: obo:CTO_0000015
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:CTO_0000016
literal: For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000016
literal: outcome measure

AnnotationAssertion
abbreviated IRI: obo:CTO_0000016
literal: outcome measurement

AnnotationAssertion
abbreviated IRI: obo:CTO_0000016
literal: clinical trial outcome measurement

AnnotationAssertion
abbreviated IRI: obo:CTO_0000017
literal: The Pan African clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000017
literal: PACTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000017
literal: Pan African clinical trial registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000017
literal: http://www.pactr.org/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000017
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000018
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the The Netherlands national trial register (NTR). The format for the registry number is “NTR” followed by a 1 to 4-digit number, e.g., NL8498.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000018
literal: NTR identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000018
literal: The Netherlands national trial register identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000018
literal: https://www.trialregister.nl/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000018
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000019
literal: The JAPIC (Japan Pharmaceutical Information Center) clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000019
literal: JapicCTI

AnnotationAssertion
abbreviated IRI: obo:CTO_0000019
literal: JAPIC clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000019
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000019
literal: https://www.japic.or.jp/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000019
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000020
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Pan African clinical trial register. The format for the registry number is “KCT” followed by a 15-digit number, e.g., PACTR202004893013257.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000020
literal: PACTR identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000020
literal: Pan African clinical trial registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000020
literal: https://pactr.samrc.ac.za/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000020
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000022
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Chinese clinical trials register (ChiCTR). The format for the registry number is “ChiCTR” followed by a 10-digit number, e.g., ChiCTR2000031589.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000022
literal: ChiCTR identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000022
literal: Chinese Clinical Trial Register number

AnnotationAssertion
abbreviated IRI: obo:CTO_0000022
literal: Chinese clinical trail registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000022
literal: http://www.chictr.org.cn/enIndex.aspx

AnnotationAssertion
abbreviated IRI: obo:CTO_0000023
literal: The Lebanese clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000023
literal: LBCTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000023
literal: Lebanese clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000023
literal: http://lbctr.emro.who.int/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000023
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000024
literal: German clinical trials register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000024
literal: DRKS

AnnotationAssertion
abbreviated IRI: obo:CTO_0000024
literal: German clinical trials register

AnnotationAssertion
abbreviated IRI: obo:CTO_0000024
literal: http://www.germanctr.de/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000024
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000025
literal: The JMACCT (Japan Medical Association, Center for Clinical Trials) clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000025
literal: JMACCT

AnnotationAssertion
abbreviated IRI: obo:CTO_0000025
literal: JMACCT clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000025
literal: https://dbcentre3.jmacct.med.or.jp/jmactr/Default_Eng.aspx

AnnotationAssertion
abbreviated IRI: obo:CTO_0000025
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000026
literal: adult (18-64)

AnnotationAssertion
abbreviated IRI: obo:CTO_0000026
literal: age_between_18_and_64

AnnotationAssertion
abbreviated IRI: obo:CTO_0000026
literal: https://clinicaltrials.gov/ct2/about-studies/glossary

AnnotationAssertion
abbreviated IRI: obo:CTO_0000028
literal: The actual total number of participants that are enrolled in a clinical study

AnnotationAssertion
abbreviated IRI: obo:CTO_0000028
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000028
literal: enrollment

AnnotationAssertion
annotation:
  literal: http://www.who.int/ictrp/network/trds/en/index.html
abbreviated IRI: obo:CTO_0000028
literal: sample size

AnnotationAssertion
abbreviated IRI: obo:CTO_0000028
literal: number of participants

AnnotationAssertion
abbreviated IRI: obo:CTO_0000028
literal: http://www.icmje.org/recommendations/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000030
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in Brazilian Registry of Clinical Trials (ReBEC). The format for the ReBEC registry number is “RBR-” followed by 6 characters, e.g., RBR-4hb9qs.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000030
literal: Brazilian Registry of Clinical Trials identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000030
literal: ReBEC identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000030
literal: Brazilian clinical trial registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000030
literal: http://www.ensaiosclinicos.gov.br/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000031
literal: Clinical trial phase that is a combination of phases 2 and 3.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000031
literal: Phase 2/3

AnnotationAssertion
abbreviated IRI: obo:CTO_0000031
literal: Phase 2/Phase 3

AnnotationAssertion
abbreviated IRI: obo:CTO_0000031
literal: Phase I/II

AnnotationAssertion
abbreviated IRI: obo:CTO_0000031
literal: clinical trial phase 2/3

AnnotationAssertion
abbreviated IRI: obo:CTO_0000031
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000032
literal: data item ....

AnnotationAssertion
abbreviated IRI: obo:CTO_0000032
literal: study result

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:CTO_0000033
literal: A type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in that clinical study.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000033
literal: Indication that participants who do not have a disease or condition, or related conditions or symptoms, under study in the clinical study are permitted to participate in the clinical study.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000033
literal: accepts healthy volunteers

AnnotationAssertion
abbreviated IRI: obo:CTO_0000033
literal: healthy volunteer criterion

AnnotationAssertion
abbreviated IRI: obo:CTO_0000033
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000034
literal: child (birth-17)

AnnotationAssertion
abbreviated IRI: obo:CTO_0000034
literal: age_between_birth_and_17_years

AnnotationAssertion
abbreviated IRI: obo:CTO_0000035
literal: A description of each primary outcome measure (or for observational studies, specific key measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment). Each primary outcome measure information includes title, description and time frame.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000035
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
annotation:
  literal: https://www.clinicaltrialsregister.eu/doc/EU_Clinical_Trials_Register_Glossary.pdf
abbreviated IRI: obo:CTO_0000035
literal: primary end point

AnnotationAssertion
annotation:
  literal: https://www.who.int/ictrp/network/trds/en/
abbreviated IRI: obo:CTO_0000035
literal: primary outcome(s)

AnnotationAssertion
abbreviated IRI: obo:CTO_0000035
literal: primary outcome measure information

AnnotationAssertion
abbreviated IRI: obo:CTO_0000035
literal: https://clinicaltrials.gov/ct2/about-studies/glossary

AnnotationAssertion
abbreviated IRI: obo:CTO_0000036
literal: The EU clinical trials register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000036
literal: EU-CTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000036
literal: EU clinical trials register

AnnotationAssertion
abbreviated IRI: obo:CTO_0000036
literal: https://eudract.ema.europa.eu/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000036
literal: https://www.clinicaltrialsregister.eu

AnnotationAssertion
abbreviated IRI: obo:CTO_0000036
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000037
literal: The UMIN (University Hospital Medical Information Network Center) clinical trials registry is a Japanese primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000037
literal: UMIN CTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000037
literal: UMIN clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000037
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000037
literal: https://www.umin.ac.jp/ctr/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000037
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000038
literal: older adult (65+)

AnnotationAssertion
abbreviated IRI: obo:CTO_0000038
literal: age_older_than_64

AnnotationAssertion
abbreviated IRI: obo:CTO_0000038
literal: https://clinicaltrials.gov/ct2/about-studies/glossary

AnnotationAssertion
abbreviated IRI: obo:CTO_0000039
literal: Data generated from measurement of experimental variables in a study, or for observational studies, from descriptions of patterns of diseases or traits or associations with exposures, risk factors or treatment.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000039
literal: outcome measure result

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000040
literal: Indicate whether a clinical study has been reviewed and approved by at least one human subjects protection review board or such review is not required per applicable law (for example, 21 CFR Part 56, 45 CFR Part 46, or other applicable regulation).

AnnotationAssertion
abbreviated IRI: obo:CTO_0000040
literal: human subjects protection review board status

AnnotationAssertion
abbreviated IRI: obo:CTO_0000041
literal: ClinicalTrials.gov is a registry of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000041
literal: The Korean clinical trials registry (Clinical Research Information Service (CRiS), Republic of Korea) is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000041
literal: CRiS

AnnotationAssertion
abbreviated IRI: obo:CTO_0000041
literal: Clinical Research Information Service, Republic of Korea

AnnotationAssertion
abbreviated IRI: obo:CTO_0000041
literal: Korean clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000041
literal: http://cris.nih.go.kr/cris/en/use_guide/cris_introduce.jsp

AnnotationAssertion
abbreviated IRI: obo:CTO_0000041
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000043
literal: Trials without phases (for example, studies of devices or behavioral interventions).

AnnotationAssertion
abbreviated IRI: obo:CTO_0000043
literal: N/A

AnnotationAssertion
abbreviated IRI: obo:CTO_0000043
literal: phase not applicable

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000044
literal: Look back using observations collected predominantly prior to subject selection and enrollment

AnnotationAssertion
abbreviated IRI: obo:CTO_0000044
literal: retrospective study design

AnnotationAssertion
abbreviated IRI: obo:CTO_0000045
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the international standard randomised controlled trial register (ISRCT). The format for the registry number is “ISRCTN” followed by a 8-digit number, e.g., ISRCTN14966673.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000045
literal: ISRCTN

AnnotationAssertion
abbreviated IRI: obo:CTO_0000045
literal: International Standard Randomised Controlled Trial Number

AnnotationAssertion
abbreviated IRI: obo:CTO_0000045
literal: International standard randomised controlled trial register identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000045
literal: http://www.isrctn.com/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000045
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000046
literal: Clinical trial phase that is a combination of phases 1 and 2.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000046
literal: Phase 1/2

AnnotationAssertion
abbreviated IRI: obo:CTO_0000046
literal: Phase 1/Phase 2

AnnotationAssertion
abbreviated IRI: obo:CTO_0000046
literal: Phase I/II

AnnotationAssertion
abbreviated IRI: obo:CTO_0000046
literal: clinical trial phase 1/2

AnnotationAssertion
abbreviated IRI: obo:CTO_0000046
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000047
literal: Look forward using periodic observations collected predominantly following subject enrollment

AnnotationAssertion
abbreviated IRI: obo:CTO_0000047
literal: prospective study design

AnnotationAssertion
abbreviated IRI: obo:CTO_0000048
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Thai clinical trials registry (TCTR). The format for the registry number is “TCTR” followed by a 11-digit number, e.g., TCTR20200405001

AnnotationAssertion
abbreviated IRI: obo:CTO_0000048
literal: TCTR identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000048
literal: Thai clinical trials registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000048
literal: http://www.clinicaltrials.in.th/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000048
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000049
literal: The Chinese clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000049
literal: ChiCTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000049
literal: Chinese clinical trial registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000049
literal: http://www.chictr.org.cn/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000049
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000050
literal: The Thai clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000050
literal: TCTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000050
literal: Thai clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000050
literal: http://www.clinicaltrials.in.th/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000050
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000051
literal: A description of the outcome measure in an interventional study or for observational studies, specific key measurement[s] or observation[s] used to describe patterns of diseases or traits or associations with exposures, risk factors or treatment.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000051
literal: outcome specification

AnnotationAssertion
abbreviated IRI: obo:CTO_0000051
literal: https://clinicaltrials.gov/ct2/about-studies/glossary

AnnotationAssertion
abbreviated IRI: obo:CTO_0000052
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Indian clinical trial register. The format for the registry number is “CRTI/” followed by a 4-digit number, followed by a slash, followed a 2-digit number, followed by a slash, followed a 6-digit number, e.g., CTRI/2020/03/024402.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000052
literal: CRTI identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000052
literal: Clinical Trials Registry - India identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000052
literal: Indian clinical trial registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000052
literal: http://ctri.nic.in/Clinicaltrials/login.php

AnnotationAssertion
abbreviated IRI: obo:CTO_0000052
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000053
literal: The Brazilian clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000053
literal: ReBec

AnnotationAssertion
abbreviated IRI: obo:CTO_0000053
literal: Brazilian clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000053
literal: http://www.ensaiosclinicos.gov.br/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000053
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000054
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Japan Registry of Clinical Trials (jRCT). The format for the registry number is “jRCTs” followed by a 9-digit number, e.g., JPRN-jRCTs031190227

AnnotationAssertion
abbreviated IRI: obo:CTO_0000054
literal: Japan registry of clinical trials identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000054
literal: jRCT clinical trial identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000054
literal: https://jrct.niph.go.jp/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000054
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000054
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000055
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Cuban public registry of clinical trials (RPCEC). The format for the registry number is “RPCEC” followed by a 8-digit number, e.g., RPCEC00000306.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000055
literal: RPCEC identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000055
literal: Cuban public registry of clinical trials identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000055
literal: http://registroclinico.sld.cu/en/home

AnnotationAssertion
abbreviated IRI: obo:CTO_0000055
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000056
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Lebanese clinical trials registry (LBCTR). The format for the registry number is “LBCTR” followed by a 10-digit number, e.g., LBCTR2020043459.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000056
literal: Lebanese clinical trials registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000056
literal: LBCTR identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000056
literal: http://lbctr.emro.who.int/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000056
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000073
literal: A primary registry is clinical trial registry in the WHO registry network that meet specific criteria for content, quality and validity, accessibility, unique identification, technical capacity and administration. Primary registries also meet the requirements of the International Clinical Trials Registry Platform (ICMJE).

AnnotationAssertion
abbreviated IRI: obo:CTO_0000073
literal: primary registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000073
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000074
literal: The Peruvian clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000074
literal: REPEC

AnnotationAssertion
abbreviated IRI: obo:CTO_0000074
literal: Peruvian clinical trial registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000074
literal: https://ensayosclinicos-repec.ins.gob.pe/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000074
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000075
literal: The Sri Lanka clinical trials registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000075
literal: SLCTR

AnnotationAssertion
abbreviated IRI: obo:CTO_0000075
literal: Sri Lanka clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000075
literal: http://www.slctr.lk/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000075
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000076
literal: ClinicalTrials.gov is a registry for clinical trials funded and maintained by NIH/NLM in US.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000076
literal: ClinicalTrials.gov

AnnotationAssertion
abbreviated IRI: obo:CTO_0000076
literal: US ClinicalTrial.gov registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000076
literal: https://clinicaltrials.gov/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000077
literal: A clinical trials registry organization is an organization that enables the registration and documentation of clinical trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000077
literal: clinical trials registry

AnnotationAssertion
abbreviated IRI: obo:CTO_0000077
literal: clinical trials registry organization

AnnotationAssertion
abbreviated IRI: obo:CTO_0000099
literal: clinical trial enrollment

AnnotationAssertion
abbreviated IRI: obo:CTO_0000100
literal: clinical trial participant

AnnotationAssertion
abbreviated IRI: obo:CTO_0000101
literal: healthy enrollee

AnnotationAssertion
abbreviated IRI: obo:CTO_0000102
literal: enrolled patient

AnnotationAssertion
abbreviated IRI: obo:CTO_0000103
literal: placebo medical intervention

AnnotationAssertion
abbreviated IRI: obo:CTO_0000104
literal: outcome measurement datum

AnnotationAssertion
abbreviated IRI: obo:CTO_0000105
literal: primary outcome measurement datum

AnnotationAssertion
abbreviated IRI: obo:CTO_0000106
literal: secondary outcome measurement datum

AnnotationAssertion
abbreviated IRI: obo:CTO_0000107
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000107
literal: 2021-06-10T13:15:41Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000107
literal: investigational molecular entity administration

AnnotationAssertion
abbreviated IRI: obo:CTO_0000108
literal: investigational molecular entity

AnnotationAssertion
abbreviated IRI: obo:CTO_0000109
literal: A clinical trial investigate some molecular entity which either will be a new drug or is already an approved drug but looking for new indications or new populations that are not stated in the drug label.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000109
literal: Asiyah Yu Lin

AnnotationAssertion
abbreviated IRI: obo:CTO_0000109
literal: drug clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000110
literal: a sponsor role that ties to a clinical trial.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000110
literal: Asiyah Yu Lin

AnnotationAssertion
abbreviated IRI: obo:CTO_0000110
literal: clinical trial sponsor role

AnnotationAssertion
abbreviated IRI: obo:CTO_0000111
literal: procedure clinical trIal

AnnotationAssertion
abbreviated IRI: obo:CTO_0000112
literal: a study design in which neither the subjects nor the investigators are permitted to know which subject is receiving which treatment

AnnotationAssertion
abbreviated IRI: obo:CTO_0000112
literal: double-blind

AnnotationAssertion
abbreviated IRI: obo:CTO_0000112
literal: double-blinded

AnnotationAssertion
abbreviated IRI: obo:CTO_0000112
literal: double blinded design

AnnotationAssertion
abbreviated IRI: obo:CTO_0000113
literal: a study design in which only the investigators are permitted to know which subject is receiving which treatment

AnnotationAssertion
abbreviated IRI: obo:CTO_0000113
literal: double blind

AnnotationAssertion
abbreviated IRI: obo:CTO_0000113
literal: double blinded

AnnotationAssertion
abbreviated IRI: obo:CTO_0000113
literal: single blinded design

AnnotationAssertion
abbreviated IRI: obo:CTO_0000114
literal: a study design in which the subjects and the investigators are permitted to know which subject is receiving which treatment

AnnotationAssertion
abbreviated IRI: obo:CTO_0000114
literal: open blind

AnnotationAssertion
abbreviated IRI: obo:CTO_0000114
literal: open label

AnnotationAssertion
abbreviated IRI: obo:CTO_0000114
literal: open blinded design

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000115
literal: Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies

AnnotationAssertion
abbreviated IRI: obo:CTO_0000115
literal: sequential design

AnnotationAssertion
abbreviated IRI: obo:CTO_0000116
literal: study design with a single group (arm)

AnnotationAssertion
abbreviated IRI: obo:CTO_0000116
literal: sinlge arm

AnnotationAssertion
abbreviated IRI: obo:CTO_0000116
literal: single arm design

AnnotationAssertion
abbreviated IRI: obo:CTO_0000117
literal: primary outcome measurement

AnnotationAssertion
abbreviated IRI: obo:CTO_0000118
literal: secondary outcome measurement

AnnotationAssertion
abbreviated IRI: obo:CTO_0000119
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000119
literal: 2021-06-10T13:15:58Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000119
literal: investigational drug administration

AnnotationAssertion
abbreviated IRI: obo:CTO_0000120
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000120
literal: 2021-06-10T13:16:26Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000120
literal: investigational supplement administration

AnnotationAssertion
abbreviated IRI: obo:CTO_0000121
literal: Corresponding to CT.gov XML tag "official_title" <xs:element name="clinical_study"> <xs:complexType> <xs:sequence> ... <xs:element name="official_title" type="xs:string" minOccurs="0"/> ...

AnnotationAssertion
abbreviated IRI: obo:CTO_0000121
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000121
literal: 2021-06-10T13:26:41Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000121
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000121
literal: hasOfficialTitle

AnnotationAssertion
abbreviated IRI: obo:CTO_0000122
literal: Corresponding to CT.gov XML tag "brief_title" <xs:element name="clinical_study"> <xs:complexType> <xs:sequence> ... <xs:element name="brief_title" type="xs:string"/> ...

AnnotationAssertion
abbreviated IRI: obo:CTO_0000122
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000122
literal: 2021-06-10T13:32:02Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000122
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000122
literal: hasBriefTitle

AnnotationAssertion
abbreviated IRI: obo:CTO_0000123
literal: Corresponding to CT.gov XML tag "primary completion date" with flag "Actual" <xs:element name="clinical_study"> <xs:complexType> <xs:sequence> ... <xs:element name="primary_completion_date" type="variable_date_struct" minOccurs="0"/> ...

AnnotationAssertion
abbreviated IRI: obo:CTO_0000123
literal: Asiyah Yu Lin,

AnnotationAssertion
abbreviated IRI: obo:CTO_0000123
literal: 2021-06-10T13:33:12Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000123
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000123
literal: hasCompletionDate

AnnotationAssertion
abbreviated IRI: obo:CTO_0000124
literal: Corresponding to CT.gov XML tag "start_date" with flag "Actual". <xs:element name="clinical_study"> <xs:complexType> <xs:sequence> ... <xs:element name="start_date" type="variable_date_struct" minOccurs="0"/>

AnnotationAssertion
abbreviated IRI: obo:CTO_0000124
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000124
literal: 2021-06-10T13:35:06Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000124
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000124
literal: hasStartDate

AnnotationAssertion
abbreviated IRI: obo:CTO_0000125
literal: Corresponding to CT.gov XML tag "phase": <xs:simpleType name="phase_enum"> <xs:restriction base="xs:string"> <xs:enumeration value="N/A"/> <xs:enumeration value="Early Phase 1"/> <xs:enumeration value="Phase 1"/> <xs:enumeration value="Phase 1/Phase 2"/> <xs:enumeration value="Phase 2"/> <xs:enumeration value="Phase 2/Phase 3"/> <xs:enumeration value="Phase 3"/> <xs:enumeration value="Phase 4"/> </xs:restriction> </xs:simpleType>

AnnotationAssertion
abbreviated IRI: obo:CTO_0000125
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000125
literal: 2021-06-10T13:36:18Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000125
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000125
literal: hasPhase

AnnotationAssertion
abbreviated IRI: obo:CTO_0000126
literal: Corresponding to CT.gov XML tag "Principal Investigator", a type of "responsible party" <xs:simpleType name="role_enum"> <xs:restriction base="xs:string"> <xs:enumeration value="Principal Investigator"/> <xs:enumeration value="Sub-Investigator"/> <xs:enumeration value="Study Chair"/> <xs:enumeration value="Study Director"/> </xs:restriction> </xs:simpleType>

AnnotationAssertion
abbreviated IRI: obo:CTO_0000126
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000126
literal: 2021-06-10T13:42:36Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000126
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000126
literal: has investigator

AnnotationAssertion
abbreviated IRI: obo:CTO_0000127
literal: Corresponding to CT.gov XML tag "collaborator", a type of "sponsors" <xs:complexType name="sponsors_struct"> <xs:sequence> <xs:element name="lead_sponsor" type="sponsor_struct"/> <xs:element name="collaborator" type="sponsor_struct" minOccurs="0" maxOccurs="unbounded"/> </xs:sequence> </xs:complexType>

AnnotationAssertion
abbreviated IRI: obo:CTO_0000127
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000127
literal: 2021-06-10T13:45:21Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000127
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000127
literal: has collaborator

AnnotationAssertion
abbreviated IRI: obo:CTO_0000128
literal: Corresponding to CT.gov XML tag: "overall_contact" <xs:element name="clinical_study"> <xs:complexType> <xs:sequence> ... <xs:element name="overall_contact" type="contact_struct" minOccurs="0"/> ...

AnnotationAssertion
abbreviated IRI: obo:CTO_0000128
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000128
literal: 2021-06-10T13:46:58Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000128
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000128
literal: has contact

AnnotationAssertion
abbreviated IRI: obo:CTO_0000129
literal: Corresponding to CT.gov XML tag : "location_countries" <xs:element name="clinical_study"> <xs:complexType> <xs:sequence> ... <xs:element name="location_countries" type="countries_struct" minOccurs="0"/> ...

AnnotationAssertion
abbreviated IRI: obo:CTO_0000129
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000129
literal: 2021-06-10T13:47:26Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000129
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000129
literal: has clinical trial site

AnnotationAssertion
abbreviated IRI: obo:CTO_0000130
literal: Corresponding to CT.gov XML tag "lead_sponsor", a type of "sponsors" <xs:complexType name="sponsors_struct"> <xs:sequence> <xs:element name="lead_sponsor" type="sponsor_struct"/> <xs:element name="collaborator" type="sponsor_struct" minOccurs="0" maxOccurs="unbounded"/> </xs:sequence> </xs:complexType>

AnnotationAssertion
abbreviated IRI: obo:CTO_0000130
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000130
literal: 2021-06-10T13:47:47Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000130
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000130
literal: has primary sponsor

AnnotationAssertion
abbreviated IRI: obo:CTO_0000131
literal: Corresponding to CT.gov XML tag "agency" <xs:simpleType name="agency_class_enum"> <xs:restriction base="xs:string"> <xs:enumeration value="NIH"/> <xs:enumeration value="U.S. Fed"/> <xs:enumeration value="Industry"/> <xs:enumeration value="Other"/> </xs:restriction> </xs:simpleType> <xs:complexType name="sponsor_struct"> <xs:sequence> <xs:element name="agency" type="xs:string"/> <xs:element name="agency_class" type="agency_class_enum" minOccurs="0"/> </xs:sequence> </xs:complexType>

AnnotationAssertion
abbreviated IRI: obo:CTO_0000131
literal: Asiyah Yu Lin, Qingliang "Leon" Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000131
literal: 2021-06-10T13:48:23Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000131
literal: https://clinicaltrials.gov/ct2/html/images/info/public.xsd

AnnotationAssertion
abbreviated IRI: obo:CTO_0000131
literal: has funding agency

AnnotationAssertion
abbreviated IRI: obo:CTO_0000132
literal: A clinical trial is conducted for the purpose of demonstrating the efficacy of a new drug in order to obtain its marketing approval by regulatory authorities (e.g. FDA in the United States and EMA in Europe). The pivotal clinical trial usually is a Phase III clinical trial, but exceptionally phase 2 studies could also be utilized as pivotal trials.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000132
literal: This is the same terms as the pre-version of this ontology: Clinical Trials Ontology - Neurodegenerative Diseases: http://www.co-ode.org/ontologies/ont.owl#Pivotal_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000132
literal: pivotal trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000132
literal: https://en.wikipedia.org/wiki/Pivotal_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000132
literal: https://www.sofpromed.com/pivotal-clinical-trials-frequently-asked-questions/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000132
literal: Asiyah Yu Lin

AnnotationAssertion
abbreviated IRI: obo:CTO_0000132
literal: 2021-06-10T16:49:17Z

AnnotationAssertion
abbreviated IRI: obo:CTO_0000132
literal: pivotal clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000200
literal: The main objective of the intervention(s) being evaluated by the clinical trial.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000200
literal: primary purpose of clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000200
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000200
literal: clinical trial primary purpose specification

AnnotationAssertion
abbreviated IRI: obo:CTO_0000201
literal: The quality of a clinical trial that studies a drug or biological product. The phase is based on the study's objective, the number of participants, and other characteristics. According to USA FDA, there are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000201
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000201
literal: clinical trial stage

AnnotationAssertion
abbreviated IRI: obo:CTO_0000201
literal: https://www.clinicaltrials.gov/ct2/help/glossary/phase

AnnotationAssertion
abbreviated IRI: obo:CTO_0000201
literal: phase

AnnotationAssertion
abbreviated IRI: obo:CTO_0000201
literal: clinical trial phase

AnnotationAssertion
abbreviated IRI: obo:CTO_0000201
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: A clinical trial phase that is designed to use an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited. [def-source: NCI]

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: Early Phase 1

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: Pre-Clinical Phase

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: clinical trial phase 0

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: http://purl.obolibrary.org/obo/NCIT_C54721

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: https://en.wikipedia.org/wiki/Clinical_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: C1882358

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: C54721

AnnotationAssertion
abbreviated IRI: obo:CTO_0000202
literal: clinical trial early phase 1

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: A clinical trial phase that represents the first-in-man trial, which tests within a small group of people (typically 20-80) to evaluate safety, determine safe dosage ranges, and begin to identify side effects. A drug's side effects could be subtle or long term, or may only happen with a few people, so phase 1 trials are not expected to identify all side effects.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: Phase 1

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: Phase I

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: http://purl.obolibrary.org/obo/NCIT_C15600

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: https://en.wikipedia.org/wiki/Clinical_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: C0920321

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: C15600

AnnotationAssertion
abbreviated IRI: obo:CTO_0000203
literal: clinical trial phase 1

AnnotationAssertion
abbreviated IRI: obo:CTO_0000204
literal: A clinical trial phase that is designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention. [def-source: NCI]

AnnotationAssertion
abbreviated IRI: obo:CTO_0000204
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000204
literal: Phase II

AnnotationAssertion
abbreviated IRI: obo:CTO_0000204
literal: http://purl.obolibrary.org/obo/NCIT_C15601

AnnotationAssertion
abbreviated IRI: obo:CTO_0000204
literal: https://en.wikipedia.org/wiki/Clinical_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000204
literal: C0282460

AnnotationAssertion
abbreviated IRI: obo:CTO_0000204
literal: C15601

AnnotationAssertion
abbreviated IRI: obo:CTO_0000204
literal: clinical trial phase 2

AnnotationAssertion
abbreviated IRI: obo:CTO_0000205
literal: A clinical trial phase that is designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo. [def-source: NCI]

AnnotationAssertion
abbreviated IRI: obo:CTO_0000205
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000205
literal: Phase III

AnnotationAssertion
abbreviated IRI: obo:CTO_0000205
literal: http://purl.obolibrary.org/obo/NCIT_C15602

AnnotationAssertion
abbreviated IRI: obo:CTO_0000205
literal: https://en.wikipedia.org/wiki/Clinical_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000205
literal: C0282461

AnnotationAssertion
abbreviated IRI: obo:CTO_0000205
literal: C15602

AnnotationAssertion
abbreviated IRI: obo:CTO_0000205
literal: clinical trial phase 3

AnnotationAssertion
abbreviated IRI: obo:CTO_0000206
literal: A clinical trial phase that is designed for a randomized, controlled trial to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed. [def-source: NCI]

AnnotationAssertion
abbreviated IRI: obo:CTO_0000206
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000206
literal: Phase IV

AnnotationAssertion
abbreviated IRI: obo:CTO_0000206
literal: https://en.wikipedia.org/wiki/Clinical_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000206
literal: C0282462

AnnotationAssertion
abbreviated IRI: obo:CTO_0000206
literal: C15603

AnnotationAssertion
abbreviated IRI: obo:CTO_0000206
literal: clinical trial phase 4

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: A clinical trial that is at Early Phase 1 or Phase 0

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: A clinical trial that is at an Early Phase i or Phase 0, which is designed to use an investigational agent that is available only in very limited quantities and which has never previously given to humans or for which there is extremely limited human experience. Phase 0 clinical trials are intended to enable researchers to understand the path of the drug in the body and its efficacy. Adverse event reporting in Phase 0 trials is expedited. [def-source: NCI]

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:CTO_0000207
literal: Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies). (Formerly listed as "Phase 0")

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: Phase 0 clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: Phase 0 trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: Pre-Clinical Trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: http://purl.obolibrary.org/obo/NCIT_C54721

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: https://en.wikipedia.org/wiki/Clinical_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000207
literal: Early Phase 1 clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000208
literal: EudraCT Number: 2007-002422-29

AnnotationAssertion
abbreviated IRI: obo:CTO_0000208
literal: Qingliang Leon Li, Asiyah Yu Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000208
literal: EudraCT identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000208
literal: https://en.wikipedia.org/wiki/EudraCT

AnnotationAssertion
abbreviated IRI: obo:CTO_0000208
literal: https://www.clinicaltrialsregister.eu/ctr-search/search

AnnotationAssertion
abbreviated IRI: obo:CTO_0000208
literal: https://www.clinicaltrialsregister.eu/ctr-search/search

AnnotationAssertion
abbreviated IRI: obo:CTO_0000208
literal: European clinical trial registry identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000208
literal: https://www.who.int/ictrp/network/primary/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000209
literal: Qingliang Leon Li, Asiyah Yu Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000209
literal: https://pubchem.ncbi.nlm.nih.gov/source/NIPH%20Clinical%20Trials%20Search%20of%20Japan

AnnotationAssertion
abbreviated IRI: obo:CTO_0000209
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000209
literal: Japan clinical trial identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000209
literal: https://www.who.int/ictrp/network/jprn2/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000210
literal: Qingliang Leon Li, Asiyah Yu Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000210
literal: JapicCTI

AnnotationAssertion
abbreviated IRI: obo:CTO_0000210
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000210
literal: JAPIC clinical trial identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000211
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in JMACCT. The format for the JMACCT registry number is “JMA-IIA” followed by a 5-digit number, e.g., JMA-IIA00391.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000211
literal: Qingliang Leon Li, Asiyah Yu Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000211
literal: JMACCT

AnnotationAssertion
abbreviated IRI: obo:CTO_0000211
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000211
literal: JMACCT clinical trial identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000212
literal: A Japan clinical trial identifier provided by the University Hospital Medical Information Network Center (UMIN-CTR)

AnnotationAssertion
abbreviated IRI: obo:CTO_0000212
literal: Qingliang Leon Li, Asiyah Yu Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000212
literal: UMIN

AnnotationAssertion
abbreviated IRI: obo:CTO_0000212
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000212
literal: UMIN-CTR clinical trial identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000213
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the ClinicalTrials.gov. The format for the ClinicalTrials.gov registry number is “NCT” followed by an 8-digit number, e.g.: NCT00000419.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000213
literal: Qingliang Leon Li, Asiyah Yu Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:CTO_0000213
literal: NCT identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000213
literal: NCT number

AnnotationAssertion
abbreviated IRI: obo:CTO_0000213
literal: National Clinical Trial identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000213
literal: https://clinicaltrials.gov/ct2/about-site/link-to

AnnotationAssertion
abbreviated IRI: obo:CTO_0000213
literal: https://www.nlm.nih.gov/bsd/policy/clin_trials.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000213
literal: USA National Clinical Trial identifier

AnnotationAssertion
abbreviated IRI: obo:CTO_0000214
literal: The date on which a study starts

AnnotationAssertion
abbreviated IRI: obo:CTO_0000214
literal: study start date

AnnotationAssertion
abbreviated IRI: obo:CTO_0000215
literal: The date that the final participant was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical study concluded according to the pre-specified protocol or was terminated. In the case of clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all of the primary outcomes.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000215
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000215
literal: primary completion

AnnotationAssertion
abbreviated IRI: obo:CTO_0000215
literal: clinical trial primary completion date

AnnotationAssertion
abbreviated IRI: obo:CTO_0000216
literal: The date the final participant was examined or received an intervention for purposes of final collection of data for the primary and secondary outcome measures and adverse events (for example, last participant’s last visit), whether the clinical study concluded according to the pre-specified protocol or was terminated.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000216
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
annotation:
  literal: http://www.icmje.org/recommendations/ http://www.who.int/ictrp/network/trds/en/index.html
abbreviated IRI: obo:CTO_0000216
literal: completion date

AnnotationAssertion
abbreviated IRI: obo:CTO_0000216
literal: clinical trial study completion date

AnnotationAssertion
abbreviated IRI: obo:CTO_0000217
literal: A textual entity that is the title of a clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000217
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000217
literal: title of clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000218
literal: A title of clinical trial that is meant for lay people understanding

AnnotationAssertion
abbreviated IRI: obo:CTO_0000218
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000218
literal: brief title

AnnotationAssertion
abbreviated IRI: obo:CTO_0000218
literal: lay title

AnnotationAssertion
abbreviated IRI: obo:CTO_0000218
literal: public title

AnnotationAssertion
abbreviated IRI: obo:CTO_0000218
literal: lay title of clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000218
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000219
literal: A title of clinical trial that is recorded as official

AnnotationAssertion
abbreviated IRI: obo:CTO_0000219
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000219
literal: full title

AnnotationAssertion
abbreviated IRI: obo:CTO_0000219
literal: scientific title

AnnotationAssertion
abbreviated IRI: obo:CTO_0000219
literal: official title of clinical trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000219
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000220
literal: a clinical trial is a medical interventional study where participants are assigned prospectively to an intervention or interventions according to a protocol to evaluate the safety and efficacy of the intervention(s) on biomedical or other health related outcomes. The Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioral treatments, process-of-care changes, preventive care, etc.

AnnotationAssertion
abbreviated IRI: obo:CTO_0000220
literal: Oliver He, Asiyah Yu Lin, Qingliang Li

AnnotationAssertion
abbreviated IRI: obo:CTO_0000220
literal: interventional trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000220
literal: https://clinicaltrials.gov/ct2/search/map

AnnotationAssertion
abbreviated IRI: obo:CTO_0000220
literal: https://en.wikipedia.org/wiki/Clinical_trial

AnnotationAssertion
abbreviated IRI: obo:CTO_0000220
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:CTO_0000220
literal: https://www.who.int/ictrp/en/

AnnotationAssertion
abbreviated IRI: obo:CTO_0000220
literal: clinical trial

AnnotationAssertion
abbreviated IRI: obo:DRON_00000005
literal: a material entity (1) containing at least one scattered molecular aggregate as part that is the bearer of an active ingredient role and (2) that is itself the bearer of a clinical drug role

AnnotationAssertion
abbreviated IRI: obo:DRON_00000005
literal: William Hogan

AnnotationAssertion
abbreviated IRI: obo:DRON_00000005
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:DRON_00000005
literal: William Hogan

AnnotationAssertion
abbreviated IRI: obo:DRON_00000005
literal: drug product

AnnotationAssertion
abbreviated IRI: obo:ERO_0000017
literal: epidemiological study

AnnotationAssertion
abbreviated IRI: obo:ERO_0000017
literal: A study of the populations and demographic of the avian flu.

AnnotationAssertion
abbreviated IRI: obo:ERO_0000017
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:ERO_0000017
literal: A human study of diseases in populations of humans or other animals, specifically how, when and where they occur. Epidemiological studies can never prove causation, epidemiological evidence can only show that this risk factor is correlated with a higher incidence of disease in the population exposed to that risk factor. The higher the correlation the more certain the association, but it cannot prove the causation.

AnnotationAssertion
abbreviated IRI: obo:ERO_0000017
literal: PERSON: Karen Corday

AnnotationAssertion
abbreviated IRI: obo:ERO_0000017
literal: http://pmep.cce.cornell.edu/profiles/extoxnet/TIB/epidemiology.html

AnnotationAssertion
abbreviated IRI: obo:ERO_0000017
abbreviated IRI: obo:ero.owl

AnnotationAssertion
abbreviated IRI: obo:ERO_0000017
literal: epidemiological study

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:ERO_0000348
literal: single group of individuals with specific characteristics.

AnnotationAssertion
abbreviated IRI: obo:ERO_0001092
literal: A blood pressure monitor is a medical device.

AnnotationAssertion
abbreviated IRI: obo:ERO_0001092
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:ERO_0001092
literal: An instrument used in the diagnosis of disease or other conditions or for use in the care, treatment, or prevention of disease that does not achieve any of its primary intended purposes by chemical action or by being metabolized.

AnnotationAssertion
abbreviated IRI: obo:ERO_0001092
literal: PERSON: Nicole Vasilevsky

AnnotationAssertion
abbreviated IRI: obo:ERO_0001092
literal: http://medical-dictionary.thefreedictionary.com/medical+device

AnnotationAssertion
abbreviated IRI: obo:ERO_0001092
abbreviated IRI: obo:ero.owl

AnnotationAssertion
abbreviated IRI: obo:ERO_0001092
literal: medical device

AnnotationAssertion
abbreviated IRI: obo:ERO_0001402
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
abbreviated IRI: obo:ERO_0001402
literal: A preliminary study to determine the practicability of a proposed health program or procedure or of a larger study and to appraise the factors that may influence its practicability. A feasibility study aims to discover those things which may affect successful study conduct on a larger scale.

AnnotationAssertion
abbreviated IRI: obo:ERO_0001402
literal: PERSON: Melanie Wilson

AnnotationAssertion
abbreviated IRI: obo:ERO_0001402
literal: Dictionary of Epidemiology, 5th edition.

AnnotationAssertion
abbreviated IRI: obo:ERO_0001402
abbreviated IRI: obo:ero.owl

AnnotationAssertion
abbreviated IRI: obo:ERO_0001402
literal: feasibility study

AnnotationAssertion
abbreviated IRI: obo:ERO_0001843
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
abbreviated IRI: obo:ERO_0001843
literal: An organization dedicated to the collection, storage and dissemination of a set of scientific or clinical data.

AnnotationAssertion
abbreviated IRI: obo:ERO_0001843
literal: PERSON: Nicole Vasilevsky

AnnotationAssertion
abbreviated IRI: obo:ERO_0001843
literal: PERSON: Scott Hoffmann

AnnotationAssertion
abbreviated IRI: obo:ERO_0001843
abbreviated IRI: obo:ero.owl

AnnotationAssertion
abbreviated IRI: obo:ERO_0001843
literal: registry

AnnotationAssertion
abbreviated IRI: obo:ERO_0001843
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: objective specification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: A directive information entity that describes an intended process endpoint. When part of a plan specification the concretization is realized in a planned process in which the bearer tries to effect the world so that the process endpoint is achieved.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: 2009-03-16: original definition when imported from OBI read: "objective is an non realizable information entity which can serve as that proper part of a plan towards which the realization of the plan is directed."

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: 2014-03-31: In the example of usage ("In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction") there is a protocol which is the ChIP assay protocol. In addition to being concretized on paper, the protocol can be concretized as a realizable entity, such as a plan that inheres in a person. The objective specification is the part that says that some protein and DNA interactions are identified. This is a specification of a process endpoint: the boundary in the process before which they are not identified and after which they are. During the realization of the plan, the goal is to get to the point of having the interactions, and participants in the realization of the plan try to do that.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: Answers the question, why did you do this experiment?

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: PERSON: Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: PERSON: Barry Smith

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: PERSON: Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: PERSON: Jennifer Fostel

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: goal specification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: OBI Plan and Planned Process/Roles Branch

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: OBI_0000217

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000005
literal: objective specification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000007
literal: Pour the contents of flask 1 into flask 2

AnnotationAssertion
abbreviated IRI: obo:IAO_0000007
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000007
literal: A directive information entity that describes an action the bearer will take.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000007
literal: Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000007
literal: OBI Plan and Planned Process branch

AnnotationAssertion
abbreviated IRI: obo:IAO_0000007
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000007
literal: action specification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: data item

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: Data items include counts of things, analyte concentrations, and statistical summaries.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: a data item is an information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: a data item that is about the outcome measured by a clinical trial.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: 2/2/2009 Alan and Bjoern discussing FACS run output data. This is a data item because it is about the cell population. Each element records an event and is typically further composed a set of measurment data items that record the fluorescent intensity stimulated by one of the lasers.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: 2009-03-16: data item deliberatly ambiguous: we merged data set and datum to be one entity, not knowing how to define singular versus plural. So data item is more general than datum.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: 2009-03-16: removed datum as alternative term as datum specifically refers to singular form, and is thus not an exact synonym.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: 2014-03-31: See discussion at http://odontomachus.wordpress.com/2014/03/30/aboutness-objects-propositions/

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: JAR: datum -- well, this will be very tricky to define, but maybe some information-like stuff that might be put into a computer and that is meant, by someone, to denote and/or to be interpreted by some process... I would include lists, tables, sentences... I think I might defer to Barry, or to Brian Cantwell Smith JAR: A data item is an approximately justified approximately true approximate belief

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: PERSON: Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: PERSON: Chris Stoeckert

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: PERSON: Jonathan Rees

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: data

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000027
literal: data item

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: information content entity

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: Examples of information content entites include journal articles, data, graphical layouts, and graphs.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: A generically dependent continuant that is about some thing.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: An information content entity is an entity that is generically dependent on some artifact and stands in relation of aboutness to some entity

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: 2014-03-10: The use of "thing" is intended to be general enough to include universals and configurations (see https://groups.google.com/d/msg/information-ontology/GBxvYZCk1oc/-L6B5fSBBTQJ).

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: information_content_entity 'is_encoded_in' some digital_entity in obi before split (040907). information_content_entity 'is_encoded_in' some physical_document in obi before split (040907). Previous. An information content entity is a non-realizable information entity that 'is encoded in' some digital or physical entity.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: PERSON: Chris Stoeckert

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: OBI_0000142

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:envo.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:ico.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:ontoneo.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
abbreviated IRI: obo:pdro.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: information content entity

AnnotationAssertion
abbreviated IRI: obo:IAO_0000030
literal: information content entity

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
literal: An information content entity whose concretizations indicate to their bearer how to realize them in a process.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
literal: 2009-03-16: provenance: a term realizable information entity was proposed for OBI (OBI_0000337) , edited by the PlanAndPlannedProcess branch. Original definition was "is the specification of a process that can be concretized and realized by an actor" with alternative term "instruction".It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
literal: 2013-05-30 Alan Ruttenberg: What differentiates a directive information entity from an information concretization is that it can have concretizations that are either qualities or realizable entities. The concretizations that are realizable entities are created when an individual chooses to take up the direction, i.e. has the intention to (try to) realize it.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
literal: 8/6/2009 Alan Ruttenberg: Changed label from "information entity about a realizable" after discussions at ICBO

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
literal: Werner pushed back on calling it realizable information entity as it isn't realizable. However this name isn't right either. An example would be a recipe. The realizable entity would be a plan, but the information entity isn't about the plan, it, once concretized, *is* the plan. -Alan

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
literal: PERSON: Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
literal: PERSON: Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000033
literal: directive information entity

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
literal: curation status specification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
literal: The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
literal: Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
literal: PERSON:Bill Bug

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
literal: GROUP:OBI:<http://purl.obolibrary.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
literal: OBI_0000266

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000078
literal: curation status specification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: report

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: Examples of reports are gene lists and investigation reports. These are not published (journal) articles but may be included in a journal article.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: a document assembled by an author for the purpose of providing information for the audience. A report is the output of a documenting process and has the objective to be consumed by a specific audience. Topic of the report is on something that has completed. A report is not a single figure. Examples of reports are journal article, patent application, grant progress report, case report (not patient record)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: 2009-03-16: comment from Darren Natale: I am slightly uneasy with the sentence "Topic of the report is on something that has completed." Should it be restricted to those things that are completed? For example, a progress report is (usually) about something that definitely has *not* been completed, or may include (only) projections. I think the definition would not suffer if the whole sentence is deleted.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: 2009-03-16: this was report of results with definition: A report is a narrative object that is a formal statement of the results of an investigation, or of any matter on which definite information is required, made by some person or body instructed or required to do so.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: 2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: 2009-08-10 Alan Ruttenberg: Larry Hunter suggests that this be obsoleted and replaced by 'document'. Alan restored as there are OBI dependencies and this merits further discussion

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: disagreement about where reports go. alan: only some gene lists are reports. Is a report all the content of some document? The example of usage suggests that a report may be part of some article. Term needs clarification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: PERSON: Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: PERSON: Melanie Courtot

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: PERSON:Chris Stoeckert

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: GROUP: OBI

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: OBI_0000099

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000088
literal: report

AnnotationAssertion
abbreviated IRI: obo:IAO_0000102
literal: data about an ontology part is a data item about a part of an ontology, for example a term

AnnotationAssertion
abbreviated IRI: obo:IAO_0000102
literal: Person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000102
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000102
literal: data about an ontology part

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: plan specification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: PMID: 18323827.Nat Med. 2008 Mar;14(3):226.New plan proposed to help resolve conflicting medical advice.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: A directive information entity with action specifications and objective specifications as parts that, when concretized, is realized in a process in which the bearer tries to achieve the objectives by taking the actions specified.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: 2009-03-16: provenance: a term a plan was proposed for OBI (OBI_0000344) , edited by the PlanAndPlannedProcess branch. Original definition was " a plan is a specification of a process that is realized by an actor to achieve the objective specified as part of the plan". It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: 2014-03-31: A plan specification can have other parts, such as conditional specifications.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: Alternative previous definition: a plan is a set of instructions that specify how an objective should be achieved

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: OBI Plan and Planned Process branch

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: OBI_0000344

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: 2/3/2009 Comment from OBI review. Action specification not well enough specified. Conditional specification not well enough specified. Question whether all plan specifications have objective specifications. Request that IAO either clarify these or change definitions not to use them

AnnotationAssertion
abbreviated IRI: obo:IAO_0000104
literal: plan specification

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred label

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred label

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred term

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred term

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred term~editor preferred label

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: PERSON:Daniel Schober

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: GROUP:OBI:<http://purl.obolibrary.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred label

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred label

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred term

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred term

AnnotationAssertion
abbreviated IRI: obo:IAO_0000111
literal: editor preferred term~editor preferred label

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
literal: example

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
literal: example of usage

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
literal: A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
literal: A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
literal: PERSON:Daniel Schober

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
literal: GROUP:OBI:<http://purl.obolibrary.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
literal: example of usage

AnnotationAssertion
abbreviated IRI: obo:IAO_0000112
literal: example of usage

AnnotationAssertion
abbreviated IRI: obo:IAO_0000114
literal: has curation status

AnnotationAssertion
abbreviated IRI: obo:IAO_0000114
literal: PERSON:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000114
literal: PERSON:Bill Bug

AnnotationAssertion
abbreviated IRI: obo:IAO_0000114
literal: PERSON:Melanie Courtot

AnnotationAssertion
abbreviated IRI: obo:IAO_0000114
literal: OBI_0000281

AnnotationAssertion
abbreviated IRI: obo:IAO_0000114
literal: has curation status

AnnotationAssertion
abbreviated IRI: obo:IAO_0000114
literal: has curation status

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: definition

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: definition

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: textual definition

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: A property representing the English language definitions of what NCI means by the concept. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: English language definitions of what NCI means by the concept. These are limited to 1024 characters. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: 2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: PERSON:Daniel Schober

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: GROUP:OBI:<http://purl.obolibrary.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: DEFINITION

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: definition

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: definition

AnnotationAssertion
abbreviated IRI: obo:IAO_0000115
literal: textual definition

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: editor note

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: PERSON:Daniel Schober

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: GROUP:OBI:<http://purl.obfoundry.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: GROUP:OBI:<http://purl.obofoundry.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: IAO:0000116

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: uberon

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: editor_note

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: 1

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: editor_note

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: editor note

AnnotationAssertion
abbreviated IRI: obo:IAO_0000116
literal: editor note

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: definition editor

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: term editor

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: 20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: PERSON:Daniel Schober

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: GROUP:OBI:<http://purl.obolibrary.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: definition editor

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: definition editor

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: term editor

AnnotationAssertion
abbreviated IRI: obo:IAO_0000117
literal: term editor

AnnotationAssertion
abbreviated IRI: obo:IAO_0000118
literal: alternative term

AnnotationAssertion
abbreviated IRI: obo:IAO_0000118
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:IAO_0000118
literal: An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000118
literal: PERSON:Daniel Schober

AnnotationAssertion
abbreviated IRI: obo:IAO_0000118
literal: GROUP:OBI:<http://purl.obolibrary.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000118
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000118
literal: alternative term

AnnotationAssertion
abbreviated IRI: obo:IAO_0000118
literal: alternative term

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: definition source

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: Formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: PERSON:Daniel Schober

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: GROUP:OBI:<http://purl.obolibrary.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: definition source

AnnotationAssertion
abbreviated IRI: obo:IAO_0000119
literal: definition source

AnnotationAssertion
abbreviated IRI: obo:IAO_0000122
literal: ready for release

AnnotationAssertion
abbreviated IRI: obo:IAO_0000123
literal: metadata incomplete

AnnotationAssertion
abbreviated IRI: obo:IAO_0000125
literal: pending final vetting

AnnotationAssertion
abbreviated IRI: obo:IAO_0000136
literal: is about

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: curator note

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: An administrative note of use for a curator but of no use for a user

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: PERSON:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: IAO:0000232

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: uberon

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: curator_notes

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: 1

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: curator_notes

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: curator note

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: curator note

AnnotationAssertion
abbreviated IRI: obo:IAO_0000232
literal: curator notes

AnnotationAssertion
abbreviated IRI: obo:IAO_0000233
literal: term tracker item

AnnotationAssertion
abbreviated IRI: obo:IAO_0000233
literal: the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/

AnnotationAssertion
abbreviated IRI: obo:IAO_0000233
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:IAO_0000233
literal: An IRI or similar locator for a request or discussion of an ontology term.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000233
literal: Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000233
literal: Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000233
literal: The 'tracker item' can associate a tracker with a specific ontology term.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000233
literal: term tracker item

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
literal: textual entity

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
literal: Words, sentences, paragraphs, and the written (non-figure) parts of publications are all textual entities

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
literal: A textual entity is a part of a manifestation (FRBR sense), a generically dependent continuant whose concretizations are patterns of glyphs intended to be interpreted as words, formulas, etc.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
literal: AR, (IAO call 2009-09-01): a document as a whole is not typically a textual entity, because it has pictures in it - rather there are parts of it that are textual entities. Examples: The title, paragraph 2 sentence 7, etc.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
literal: MC, 2009-09-14 (following IAO call 2009-09-01): textual entities live at the FRBR (http://en.wikipedia.org/wiki/Functional_Requirements_for_Bibliographic_Records) manifestation level. Everything is significant: line break, pdf and html versions of same document are different textual entities.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
literal: PERSON: Lawrence Hunter

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
literal: text

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000300
literal: textual entity

AnnotationAssertion
abbreviated IRI: obo:IAO_0000310
literal: document

AnnotationAssertion
abbreviated IRI: obo:IAO_0000310
literal: A journal article, patent application, laboratory notebook, or a book

AnnotationAssertion
abbreviated IRI: obo:IAO_0000310
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:IAO_0000310
literal: A collection of information content entities intended to be understood together as a whole

AnnotationAssertion
abbreviated IRI: obo:IAO_0000310
literal: PERSON: Lawrence Hunter

AnnotationAssertion
abbreviated IRI: obo:IAO_0000310
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000310
literal: document

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
literal: imported from

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
literal: For external terms/classes, the ontology from which the term was imported

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
literal: PERSON:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
literal: PERSON:Melanie Courtot

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
literal: GROUP:OBI:<http://purl.obolibrary.org/obo/obi>

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
literal: imported from

AnnotationAssertion
abbreviated IRI: obo:IAO_0000412
literal: imported from

AnnotationAssertion
abbreviated IRI: obo:IAO_0000422
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
abbreviated IRI: obo:IAO_0000422
literal: A textual entity that is used as directive to deliver something to a person, or organization

AnnotationAssertion
abbreviated IRI: obo:IAO_0000422
literal: 2010-05-24 Alan Ruttenberg. Use label for the string representation. See issue https://github.com/information-artifact-ontology/IAO/issues/59

AnnotationAssertion
abbreviated IRI: obo:IAO_0000422
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000422
literal: postal address

AnnotationAssertion
abbreviated IRI: obo:IAO_0000429
literal: email address

AnnotationAssertion
abbreviated IRI: obo:IAO_0000429
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
abbreviated IRI: obo:IAO_0000429
literal: Alan Ruttenberg 1/3/2012 - Provisional id, see issue at https://github.com/information-artifact-ontology/IAO/issues/130&thanks=130&ts=1325636583

AnnotationAssertion
abbreviated IRI: obo:IAO_0000429
literal: Person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000429
literal: Person:Chris Stoeckart

AnnotationAssertion
abbreviated IRI: obo:IAO_0000429
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000429
literal: email address

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: The sentence "The article has Pubmed ID 12345." contains a CRID that has two parts: one part is the CRID symbol, which is '12345'; the other part denotes the CRID registry, which is Pubmed.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: An information content entity that consists of a CRID symbol and additional information about the CRID registry to which it belongs.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: 2014-05-05: In defining this term we take no position on what the CRID denotes. In particular do not assume it denotes a *record* in the CRID registry (since the registry might not have 'records').

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: Alan, IAO call 20101124: potentially the CRID denotes the instance it was associated with during creation.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: Note, IAO call 20101124: URIs are not always CRID, as not centrally registered. We acknowledge that CRID is a subset of a larger identifier class, but this subset fulfills our current needs. OBI PURLs are CRID as they are registered with OCLC. UPCs (Universal Product Codes from AC Nielsen)are not CRID as they are not centrally registered.

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: PERSON: Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: PERSON: Bill Hogan

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: PERSON: Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: PERSON: Melanie Courtot

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: CRID

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: Original proposal from Bjoern, discussions at IAO calls

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
abbreviated IRI: obo:iao.owl

AnnotationAssertion
annotation:
  literal: http://www.icmje.org/recommendations/ http://www.who.int/ictrp/network/trds/en/index.html
abbreviated IRI: obo:IAO_0000578
literal: Primary Registry and Trial Identifying Number

AnnotationAssertion
abbreviated IRI: obo:IAO_0000578
literal: centrally registered identifier

AnnotationAssertion
abbreviated IRI: obo:IAO_0000600
literal: elucidation

AnnotationAssertion
abbreviated IRI: obo:IAO_0000600
literal: person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000600
literal: Person:Barry Smith

AnnotationAssertion
abbreviated IRI: obo:IAO_0000600
literal: Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms

AnnotationAssertion
abbreviated IRI: obo:IAO_0000600
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000600
literal: elucidation

AnnotationAssertion
abbreviated IRI: obo:IAO_0000600
literal: elucidation

AnnotationAssertion
abbreviated IRI: obo:IAO_0000601
literal: has associated axiom(nl)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000601
literal: Person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000601
literal: Person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000601
literal: An axiom associated with a term expressed using natural language

AnnotationAssertion
abbreviated IRI: obo:IAO_0000601
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000601
literal: has associated axiom(nl)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000601
literal: has associated axiom(nl)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000602
literal: has associated axiom(fol)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000602
literal: Person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000602
literal: Person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:IAO_0000602
literal: An axiom expressed in first order logic using CLIF syntax

AnnotationAssertion
abbreviated IRI: obo:IAO_0000602
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0000602
literal: has associated axiom(fol)

AnnotationAssertion
abbreviated IRI: obo:IAO_0000602
literal: has associated axiom(fol)

AnnotationAssertion
abbreviated IRI: obo:IAO_0010000
abbreviated IRI: obo:iao.owl

AnnotationAssertion
abbreviated IRI: obo:IAO_0010000
literal: has axiom label

AnnotationAssertion
abbreviated IRI: obo:MS_1000590
literal: Home institution of the contact person.

AnnotationAssertion
abbreviated IRI: obo:MS_1000590
abbreviated IRI: obo:ms.owl

AnnotationAssertion
abbreviated IRI: obo:MS_1000590
literal: value-type:xsd:string

AnnotationAssertion
abbreviated IRI: obo:MS_1000590
literal: MS

AnnotationAssertion
abbreviated IRI: obo:MS_1000590
literal: MS:1000590

AnnotationAssertion
abbreviated IRI: obo:MS_1000590
literal: contact affiliation

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_1
abbreviated IRI: obo:ncbitaxon.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_1
literal: GC_ID:1

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_1
literal: ncbi_taxonomy

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_1
literal: all

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_1
literal: root

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_131567
abbreviated IRI: obo:ncbitaxon.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_131567
literal: GC_ID:1

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_131567
literal: ncbi_taxonomy

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_131567
literal: biota

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_131567
literal: cellular organisms

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
abbreviated IRI: obo:ncbitaxon.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
abbreviated IRI: obo:NCBITaxon_superkingdom

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: GC_ID:1

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: PMID:23020233

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: PMID:30257078

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: eucaryotes

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: eukaryotes

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: ncbi_taxonomy

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: Eucarya

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: Eucaryotae

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: Eukarya

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: Eukaryotae

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: eukaryotes

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_2759
literal: Eukaryota

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_40674
abbreviated IRI: obo:ncbitaxon.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_40674
abbreviated IRI: obo:NCBITaxon_class

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_40674
literal: GC_ID:1

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_40674
literal: mammals

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_40674
literal: ncbi_taxonomy

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_40674
literal: mammals

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_40674
literal: Mammalia

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_7742
abbreviated IRI: obo:ncbitaxon.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_7742
literal: GC_ID:1

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_7742
literal: Vertebrata

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_7742
literal: vertebrates

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_7742
literal: ncbi_taxonomy

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_7742
literal: vertebrates

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_7742
literal: Vertebrata <vertebrates>

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapiens

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapiens

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: human

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: human being

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: man

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: person

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
abbreviated IRI: obo:envo.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
abbreviated IRI: obo:ncbitaxon.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
abbreviated IRI: obo:NCBITaxon_species

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: GC_ID:1

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: human

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: man

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: ncbi_taxonomy

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Home sapiens

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sampiens

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapeins

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapian

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapians

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapien

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapience

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapiense

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapients

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapines

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo spaiens

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo spiens

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Humo sapiens

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: humans

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapiens

AnnotationAssertion
abbreviated IRI: obo:NCBITaxon_9606
literal: Homo sapiens

AnnotationAssertion
abbreviated IRI: obo:NCIT_A11
literal: A property created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are the contributing source.

AnnotationAssertion
abbreviated IRI: obo:NCIT_A11
literal: An association created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are a contributing source.

AnnotationAssertion
abbreviated IRI: obo:NCIT_A11
literal: A11

AnnotationAssertion
abbreviated IRI: obo:NCIT_A11
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_A11
literal: Has_NICHD_Parent

AnnotationAssertion
abbreviated IRI: obo:NCIT_A11
literal: Has_NICHD_Parent

AnnotationAssertion
abbreviated IRI: obo:NCIT_A11
literal: Has_NICHD_Parent

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: Records containing any interim or final results, as well as clinical and statistical descriptions, presentations, analyses and interpretations of any therapeutic, prophylactic, or diagnostic agent used in human subjects in a clinical trial.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: C115575

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: Intellectual Product

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: Clinical Trial Final Report

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: C3889645

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: CareLex

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: A written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report. [ICH E3]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: Subcategory name for the eTMF domain used to classify clinical study report documents.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: CTrial Fin Rept Subcat

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: Central Trial Final Reports Subcategory

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: Clinical Trial Final Report

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: Reports

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: final report

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C115575
literal: Clinical Trial Final Report

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C129000
literal: An observational study that is also considered to be a Patient Registry. This type of study should only be registered once in the Protocol Registration and Results System (PRS), by the sponsor responsible for the primary data collection and analysis.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: C129000

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: Patient Registry Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: C0920631

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: PATIENT REGISTRY

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: Patient Registry Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077

AnnotationAssertion
abbreviated IRI: obo:NCIT_C129000
literal: Patient Registry Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: An intervention of a device product is being evaluated to determine the feasibility of the product or to test a prototype device and not health outcomes. Such studies are conducted to confirm the design and operating specifications of a device before beginning a full clinical trial. (ClinicalTrials.gov)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: C139174

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: Device Feasibility Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: CL526612

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: An intervention of a device product is being evaluated to determine the feasibility of the product or to test a prototype device and not health outcomes. Such studies are conducted to confirm the design and operating specifications of a device before beginning a full clinical trial. (ClinicalTrials.gov)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: DEVICE FEASIBILITY

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: Device Feasibility

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: Device Feasibility Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147067

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C139174
literal: Device Feasibility Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: The nature of the investigation or the investigational use for which clinical study is being done.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: C142175

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: Study Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: CL540168

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: Describes the role the study plays in determining the interventions a subject receives.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: STYPE

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: Study Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C142191

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: Study Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142175
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C142660
literal: Participants are assigned to intervention groups by chance

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: The process of resource distribution that is done by chance.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: C142660

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: Random Allocation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: CL540611

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: Assignment of subjects to treatment (or control) groups in an unpredictable way. NOTE: in a blinded study, assignment sequences are concealed, but available for disclosure in the event a subject has an adverse experience.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: Random Allocation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: random allocation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: randomized

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C142660
literal: Random Allocation

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C147141
literal: The main objective of the intervention(s) being evaluated by the clinical trial.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: The principal reason or intention for the execution of an interventional or non-interventional clinical study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: C147141

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: Idea or Concept

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: Study Primary Purpose

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: CL545057

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: The principal reason or intention for the execution of an interventional or non-interventional clinical study. (NCI)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: Study Primary Purpose

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: Study Primary Purpose

AnnotationAssertion
abbreviated IRI: obo:NCIT_C147141
literal: http://www.icmje.org/recommendations/ http://www.who.int/ictrp/network/trds/en/index.html

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: C15238

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Therapeutic or Preventive Procedure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Gene Therapy

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Gene Therapy

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: C0017296

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: CTRP

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Application of genetic material into cells in order to correct an inherited or acquired disease.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Treatment of human disease by gene transfer.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Treatment that alters a gene. In studies of gene therapy for cancer, researchers are trying to improve the body's natural ability to fight the disease or to make the cancer cells more sensitive to other kinds of therapy.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Gene_Therapy

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Gene therapy techniques attempt to replace a faulty or missing gene associated with a particular disease, mediate localized delivery of a protein producing specified therapeutic effects, or introduce new cellular functions.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: DNA Therapy

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: GENETIC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Gene Therapy

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Gene Transfer Procedure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Gene transfer

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15238
literal: Genetic

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Intervention, Genetic

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Molecular Biology, Gene Therapy

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: gene therapy

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C118169

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99078

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15238
literal: Gene Therapy

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: A multidisciplinary field of inquiry that examines the costs, quality, accessibility, delivery, organization, financing, and outcomes of health care services.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15245
literal: One or more interventions for evaluating the delivery, processes, management, organization, or financing of healthcare.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: C15245

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: Health Services Research

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: C0018757

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: A type of study designed to evaluate the delivery, processes, management, organization or financing of health care. (ClinicalTrials.gov)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: Health_Services_Research

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: HEALTH SERVICES RESEARCH

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: Health Services Research

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147067

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15245
literal: Health Services Research

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
abbreviated IRI: obo:NCIT_C25218

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: C15329

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Health Care Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical Procedure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical Procedure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: C0543467

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: CPTAC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: CTRP

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: NICHD

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: A procedure to remove or repair a part of the body or to find out whether disease is present. An operation.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical_Procedure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical Procedure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgery

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgically Treated

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Operation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgery

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical Interventions

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical Procedure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical Procedures

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgically

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Type of Surgery

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: surgery

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C118169

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156952

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156953

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C156954

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157524

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157526

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157527

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157528

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157529

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157530

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157532

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157533

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157534

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159412

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90259

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: Surgical Procedure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15329
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15600
literal: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: C15600

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Phase I Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: C0920321

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: The first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the best dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, phase I trials usually include only a small number of patients who have not been helped by other treatments.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. NOTE: These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid Phase 2 studies. The total number of subjects and patients included in Phase 1 studies varies with the drug, but is generally in the range of 20 to 80. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. [after FDA CDER handbook, ICH E8]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. NOTE: These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase I studies varies with the drug, but is generally in the range of 20 to 80. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. [After FDA CDER Handbook, ICH E8] (CDISC glossary)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Phase_I_Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: 1

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Clinical Trials, Phase I

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Early-Stage Clinical Trials

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: PHASE I TRIAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Phase 1 Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Phase I Clinical Trials

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Phase I Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Phase I Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Phase I Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Trial Phase 1

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: phase 1

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: phase I trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15600
literal: Phase I Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15601
literal: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: C15601

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase II Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: C0282460

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. NOTE: Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. [after FDA CDER handbook, ICH E8]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase 2. Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. NOTE: Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase_II_Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: 2

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Clinical Trials, Phase II

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: PHASE II TRIAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase 2 Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase II Clinical Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase II Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase II Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase II Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Trial Phase 2

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: phase 2

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: phase II trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15601
literal: Phase II Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: A clinical research protocol designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15602
literal: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: C15602

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase III Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: C0282461

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: A study to compare the results of people taking a new treatment with the results of people taking the standard treatment (for example, which group has better survival rates or fewer side effects). In most cases, studies move into phase III only after a treatment seems to work in phases I and II. Phase III trials may include hundreds of people.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase 3. Studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to confirm efficacy and evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. NOTE: Phase 3 studies usually include from several hundred to several thousand subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained and are intended to gather the additional information about effectiveness and safety that is needed to confirm efficacy and evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. NOTE: Phase 3 studies usually include from several hundred to several thousand subjects. [after FDA CDER handbook, ICH E8]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase_III_Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: 3

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Clinical Trials, Phase III

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: PHASE III TRIAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase 3 Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase III Clinical Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase III Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase III Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase III Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase III Trials

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Trial Phase 3

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: phase 3

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: phase III trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15602
literal: Phase III Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: A randomized, controlled trial that is designed to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15603
literal: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: C15603

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Phase IV Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: C0282462

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: After a treatment has been approved and is being marketed, it is studied in a phase IV trial to evaluate side effects that were not apparent in the phase III trial. Thousands of people are involved in a phase IV trial.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Phase 4. Postmarketing (Phase 4) studies to delineate additional information about the drug's risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval. NOTE: These studies could include, but would not be limited to, studying different doses or schedules of administration than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or use of the drug over a longer period of time. [After FDA CDER Handbook, ICH E8] (CDISC glossary)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Post approval studies to delineate additional information about the drug's risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval. NOTE: These studies could include, but would not be limited to, studying different doses or schedules of administration than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or use of the drug over a longer period of time. [after FDA CDER handbook, ICH E8]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Phase_IV_Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: 4

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Clinical Trials, Phase IV

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: PHASE IV TRIAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Phase 4 Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Phase IV Clinical Trials

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Phase IV Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Phase IV Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Trial Phase 4

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: phase 4

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: phase IV trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15603
literal: Phase IV Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: A clinical research protocol designed to study the safety, dosage levels and response to new treatment. Phase I/II trials combine a Phase I and a Phase II trial of the same treatment into a single protocol.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15693
literal: Trials that are a combination of phases 1 and 2.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: C15693

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: Phase I/II Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: C1519043

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: A class of clinical study that combines elements characteristic of traditional Phase I and Phase II trials. See also Phase I, Phase II.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: A trial to study the safety, dosage levels, and response to a new treatment.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: Phase_I_II_Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: 1-2

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: PHASE I/II TRIAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: Phase I/II Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: Phase I/II trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: Trial Phase 1-2

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: Trial Phase 1/2

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15693
literal: Phase I/II Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: A type of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15694
literal: Trials that are a combination of phases 2 and 3.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: C15694

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: Phase II/III Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: C1519042

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: A class of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: A trial to study response to a new treatment and the effectiveness of the treatment compared with the standard treatment regimen.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: Phase_II_III_Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: 2-3

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: PHASE II/III TRIAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: Phase II/III Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: Trial Phase 2-3

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: Trial Phase 2/3

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: phase II/III trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66737

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15694
literal: Phase II/III Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: Fundamental research designed to obtain or increase general scientific knowledge.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C15714
literal: One or more interventions for examining the basic mechanism of action (for example, physiology or biomechanics of an intervention).

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: C15714

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: Basic Research

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: C0681833

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: A type of study designed to examine the basic mechanism of action (e.g., physiology, biomechanics) of an intervention. (ClinicalTrials.gov)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: Basic_Science

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: BASIC SCIENCE

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: Basic Research

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: Basic Science

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: Basic Science Research

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147067

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C15714
literal: Basic Research

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: Studies among cancer patients and healthy populations that involve no intervention or alteration in the status of the participants.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: C16084

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: Observational Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: C1518527

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: A type of study in which individuals are observed or certain outcomes are measured. No attempt is made to affect the outcome (for example, no treatment is given).

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: Studies in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: Observational_Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: OBSERVATIONAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: Observational Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: Observational Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: observational study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077

AnnotationAssertion
abbreviated IRI: obo:NCIT_C16084
literal: Observational Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:NCIT_C161319
literal: The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C161319
literal: The name(s) of the disease(s) or condition(s) studied in the clinical study, or the focus of the clinical study. Use, if available, appropriate descriptors from NLM's Medical Subject Headings (MeSH)-controlled vocabulary thesaurus or terms from another vocabulary, such as the Systematized Nomenclature of Medicine—Clinical Terms (SNOMED CT), that has been mapped to MeSH within the Unified Medical Language System (UMLS) Metathesaurus.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: C161319

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: Qualitative Concept

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: Condition or Disease under Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: Condition or Disease under Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

AnnotationAssertion
annotation:
  literal: https://www.who.int/ictrp/network/trds/en/
abbreviated IRI: obo:NCIT_C161319
literal: health condition(s) or problem(s) studied

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: target disease

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: condition

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C160921

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C161319
literal: Condition or Disease under Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: The distinguishing qualities or prominent aspects of an individual person.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: C19332

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: Organism Attribute

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: Personal Attribute

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: C0681884

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: Personal_Attribute

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: Personal

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: Personal Attribute

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: Subject Characteristics

AnnotationAssertion
abbreviated IRI: obo:NCIT_C19332
literal: Personal Attribute

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:NCIT_C25150
literal: A type of eligibility criteria that indicates the age a person must be to participate in a clinical study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: How long something has existed; elapsed time since birth.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
abbreviated IRI: obo:NCIT_C89335

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: C25150

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Organism Attribute

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Age

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: C0001779

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: FDA

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: NICHD

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: How long something has existed; elapsed time since birth. (NCI)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: The time elapsed since birth.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Age

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Chronological Age

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: AGE

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Age

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Aged

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Chronological Age

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Postnatal Age

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: age

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C118466

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C19752

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C54447

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C77526

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C83187

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C83188

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90007

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90009

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
IRI: http://purl.oboInOwlInOwllibrary.org/oboInOwlInOwl/NCIT_C90259

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25150
literal: Age

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: C25320

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Intellectual Product

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Clinical Study Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: C1507394

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: BRIDG

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: CareLex

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: A detailed plan of a scientific or medical experiment, treatment, or procedure. In clinical trials, it states what the study will do, how it will be done, and why it is being done. It explains how many people will be in the study, who is eligible to take part in it, what study drugs or other interventions will be given, what tests will be done and how often, and what information will be collected.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: A discrete, structured plan (that persists over time) of a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. NOTE(S): The term "protocol" is somewhat overloaded and must be qualified to provide semantic context. Therefore the term "study protocol" was chosen to disambiguate it from other protocols. In previous versions of BRIDG, there was one class for StudyProtocol. However this too represented multiple distinct aspects of the semantics of study protocol, each of which have now been split into separate classes:- The StudyProtocol class represents the content of the study protocol and can exist even before the information is put into document form. - The details of the structured plan for the study protocol are represented by the StudyProtocolVersion, so named because any aspect of the definition can change from version to version. These details include, but are not limited to, the characteristics, specifications, objective(s), background, the pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization).- The protocol and its versions can each be represented in document form, respectively StudyProtocolDocument and StudyProtocolDocumentVersion. A StudyProtocolDocument groups the various document versions (StudyProtocolDocumentVersions).- The conduct of a study based on a study protocol definition is represented by the StudyExecution class.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the trial, but these could be represented in other protocol referenced documents. [NCI]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: See protocol.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Clinical Study Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Clinical Trial Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Full Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Prot

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Protocol Amendment

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Study Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: StudyProtocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Trial Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: clinical protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159501

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159503

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C25320
literal: Clinical Study Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: A person or organization that supports or champions something.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: C48355

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: Human

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: C1711305

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: Applicant

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C48355
literal: Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: A type of study designed to evaluate method(s) aimed at identifying a disease or condition.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C49653
literal: One or more interventions are being evaluated for identifying a disease or health condition.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: C49653

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: Diagnosis Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: C1704656

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: A type of study designed to evaluate intervention(s) aimed at identifying a disease or condition.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: Diagnosis_Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: DIAGNOSIS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: Diagnosis Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: Diagnostic Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49653
literal: Diagnosis Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: A type of study protocol designed to evaluate intervention(s) for disease treatment.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C49656
literal: One or more interventions are being evaluated for treating a disease, syndrome, or condition.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: C49656

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: Treatment Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: C3161471

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: A type of study designed to evaluate intervention(s) for treatment of disease, syndrome or condition.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: Treatment_Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: TREATMENT

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: Therapy Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: Treatment Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49656
literal: Treatment Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: A type of study protocol designed to evaluate intervention(s) for disease prevention.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C49657
literal: One or more interventions are being assessed for preventing the development of a specific disease or health condition.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: C49657

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: Prevention Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: C1706420

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: A type of study designed to identify actions necessary to permanently eliminate or reduce the long-term risk to human life as a result of a particular medication or treatment regimen.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: Prevention_Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: PREVENTION

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: Prevention Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: Preventive Clinical Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: Prophylaxis Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66739

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49657
literal: Prevention Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: The number of subjects entered in a clinical trial.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: C49692

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Group Attribute

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Planned Subject Number

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: C1709561

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: The number of subjects in a class or group (including the total for the entire trial) intended to be enrolled in a trial to reach the planned sample size. Target enrollments are set so that statistical and scientific objectives of a trial will have a likelihood of being met as determined by agreement, algorithm, or other specified process.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: The planned number of subjects to be entered in a clinical trial. (NCI)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Planned_Subject_Number

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Anticipated Enrollment

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: PLANSUB

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Planned Enrollment

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Planned Number of Subjects

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Planned Subject Number

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Target Enrollment

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: target enrollment

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: target number

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: target size

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: Planned Subject Number

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:NCIT_C49692
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: The distribution of resources over various time periods, products, operations, or investments.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C52580
literal: The method by which participants are assigned to arms in a clinical trial.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: C52580

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: Allocation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: C1706778

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: The process of assigning subjects to particular treatment groups or cohorts in a clinical study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: Allocation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: Allocation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: Subject Allocation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C147066

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: Allocation

AnnotationAssertion
abbreviated IRI: obo:NCIT_C52580
literal: https://www.clinicaltrials.gov/ct2/about-studies/glossary

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: Information regarding the means of contacting a person or group.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: C60776

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: Contact Information

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: C1880174

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: Contact_Information

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: Contact Info

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: Contact Information

AnnotationAssertion
abbreviated IRI: obo:NCIT_C60776
literal: Contact Information

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: C70793

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: Health Care Related Organization

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: Clinical Study Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: C2347796

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: CareLex

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: An entity that is responsible for the initiation, management, and/or financing of a clinical study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: An entity that is responsible for the initiation, management, and/or financing of a clinical study.[NCI]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. NOTE: If there is also a secondary sponsor, the responsible entity would be considered the primary sponsor. A corporation or agency whose employees conduct the investigation is considered a sponsor and the employees are considered investigators. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP] See also secondary sponsor.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: Clinical_Study_Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: CLINICAL STUDY SPONSOR

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: Clinical Study Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: SPONSOR

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: Study Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C114548

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C154681

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C78735

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C83187

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C83188

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70793
literal: Clinical Study Sponsor

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/results_definitions.html
abbreviated IRI: obo:NCIT_C70817
literal: The written description of the clinical study, including objective(s), design, and methods. It may also include relevant scientific background and statistical considerations (if the protocol document includes the statistical analysis plan, use "Study Protocol with SAP and/or ICF" option). Note: All amendments approved by a human subjects protection review board (if applicable), before the time of submission and that apply to all clinical trial Facility Locations must be included.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: C70817

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: Intellectual Product

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: Study Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: C2348563

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study, intervention description, and method of data analysis.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: Study_Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: Study Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132310

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: Study Protocol

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70817
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: C70840

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: Blinded Clinical Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: C2347038

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: A study in which the subject, the investigator, or anyone assessing the outcome is unaware of the treatment assignment(s). NOTE: Blinding is used to reduce the potential for bias. [Modified ICH E6 Glossary] See also blinding/masking, double-blind study, single-blind study, triple-blind study; contrast with open-label or unblinded study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: A type of study in which the patients (single-blinded) or the patients and their doctors (double-blinded) do not know which drug or treatment is being given. The opposite of a blinded study is an open label study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: Blinded_Clinical_Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: Blind Clinical Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: Blinded Clinical Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: Blinded Clinical Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: Masked Clinical Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: blinded study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C70840
literal: Blinded Clinical Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: Clinical studies testing the efficacy of devices, techniques, procedures, or tests for the purpose of detecting the presence of disease, usually before there are any symptoms.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C71485
literal: One or more interventions are assessed or examined for identifying a condition, or risk factors for a condition, in people who are not yet known to have the condition or risk factor.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: C71485

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: Screening Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: C2348164

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: A type of study designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor). (Clinicaltrials.gov)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: Trials conducted to detect persons with early, mild, and asymptomatic disease.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: Screening_Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: SCREENING

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: Screening Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: Screening Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: screening trials

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71485
literal: Screening Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: Clinical studies intended to improve the comfort and quality of life for the patient using drugs, nutritional, dietary, behavioral or other interventions.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C71486
literal: One or more interventions are evaluated for maximizing comfort, minimizing side effects, or mitigating against a decline in the participant's health or function.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: C71486

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: Supportive Care Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: C2348611

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: A type of study designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease. (ClinicalTrials.gov)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: Supportive_Care_Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: SUPPORTIVE CARE

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: Supportive Care Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: Supportive Care Trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66736

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C71486
literal: Supportive Care Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: A type of clinical study in which two or more treatments are given alone and in combination, such that all possible combinations are represented across the treatment arms, and are compared in parallel against the study control group.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C82638
literal: Two or more interventions, each alone and in combination, are evaluated in parallel against a control group

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: C82638

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: Factorial Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: C2826344

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: Two or more interventions, each alone or in combination, are evaluated in parallel against a control group. This study design allows for the comparison of active drug to placebo, presence of drug-drug interactions, and comparison of active drugs against each other.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: Factorial_Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: FACTORIAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: Factorial Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C89967

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99076

AnnotationAssertion
abbreviated IRI: obo:NCIT_C82638
literal: Factorial Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C84336
literal: Any of two or more parties working jointly towards a common goal.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C84336
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C84336
literal: C84336

AnnotationAssertion
abbreviated IRI: obo:NCIT_C84336
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C84336
literal: Collaborator

AnnotationAssertion
abbreviated IRI: obo:NCIT_C84336
literal: C2827395

AnnotationAssertion
abbreviated IRI: obo:NCIT_C84336
literal: Collaborator

AnnotationAssertion
abbreviated IRI: obo:NCIT_C84336
literal: Collaborator

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: The country in which the test is conducted.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: C90467

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: Geographic Area

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: Test Facility Country

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: C2983675

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: The country of the place in which a nonclinical laboratory study takes place, i.e., actually uses the test article in a test system. Testing facility includes any establishment required to register under section 510 of the act that conducts nonclinical laboratory studies and any consulting laboratory described in section 704 of the act that conducts such studies. Testing facility encompasses only those operational units that are being or have been used to conduct nonclinical laboratory studies. (FDA)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: TFCNTRY

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: Test Facility Country

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90007

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90009

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90467
literal: Test Facility Country

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: The name of the place in which a test is conducted.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: C90469

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: Intellectual Product

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: Test Facility Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: C2983677

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: The name of the place in which a nonclinical laboratory study takes place, i.e., actually uses the test article in a test system. Testing facility includes any establishment required to register under section 510 of the act that conducts nonclinical laboratory studies and any consulting laboratory described in section 704 of the act that conducts such studies. Testing facility encompasses only those operational units that are being or have been used to conduct nonclinical laboratory studies. (FDA)

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: TSTFNAM

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: Test Facility Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C77526

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90007

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C90009

AnnotationAssertion
abbreviated IRI: obo:NCIT_C90469
literal: Test Facility Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: A condition that is a focus of the study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: C93360

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: Qualitative Concept

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: Study Condition

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: C2985574

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: BRIDG

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: A condition that is a focus of the study.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: Study Condition

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: StudyCondition

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159501

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C159503

AnnotationAssertion
abbreviated IRI: obo:NCIT_C93360
literal: Study Condition

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: Studies in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: C98388

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: Interventional Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: C3274035

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: CDISC-GLOSS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: A trial which intervenes with the inviolability of the trial subject for the purpose of the investigation. For example, the administration of an investigational medical product to the trial subject or use of some extra means of intervention (i.e., samples, tests, or questionnaires) that would not otherwise be used. [Clinical Trial Directive EC/20/2001 definitions]

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: Studies in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: INTERVENTIONAL

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: Interventional Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: interventional clinical trial

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67497

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98388
literal: Interventional Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: A sequence of letters, numbers, or other characters that uniquely identifies a clinical trial within a clinical trial registry.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: C98714

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: Intellectual Product

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: Clinical Trial Registry Identifier

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: C3274381

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: Identification numbers assigned to the protocol by clinicaltrials.gov, EudraCT, or other registries.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: Clinical Trial Registry Identifier

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: REGID

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: Registry Identifier

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: Trial Identifying Number

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: Clinical Trial Registry Identifier

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98714
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: Studies that provide a means for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet the eligibility criteria for enrollment, or who are otherwise unable to participate in another clinical study. Expanded Access studies include individual-patient IND, treatment IND, compassionate use, emergency use or continued access.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C98722
literal: An investigational drug product (including biological product) available through expanded access for patients who do not qualify for enrollment in a clinical trial. Expanded Access includes all expanded access types under section 561 of the Federal Food, Drug, and Cosmetic Act: (1) for individual patients, including emergency use; (2) for intermediate-size patient populations; and (3) under a treatment IND or treatment protocol.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: C98722

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: Research Activity

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: Expanded Access Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: C3274389

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: Studies that provide a means for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet the eligibility criteria for enrollment, or who are otherwise unable to participate in another clinical study. Expanded Access studies include individual-patient IND, treatment IND, compassionate use, emergency use or continued access.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: EXPANDED ACCESS

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: Expanded Access Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C132298

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C99077

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: Expanded Access Study

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98722
literal: https://prsinfo.clinicaltrials.gov/expanded_access_definitions.html

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:NCIT_C98747
literal: For each intervention studied in the clinical study, the general type of intervention.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: The kind of product or procedure studied in a trial.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: C98747

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: Functional Concept

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: Intervention Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: C3274412

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: The kind of product or procedure studied in a trial.

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: INTTYPE

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: Intervention Type

AnnotationAssertion
annotation:
  literal: http://www.icmje.org/recommendations/ http://www.who.int/ictrp/network/trds/en/index.html
abbreviated IRI: obo:NCIT_C98747
literal: intervention

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98747
literal: Intervention Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: C98772

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: Intellectual Product

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: Primary Outcome Measure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: C3274433

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s).

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: OUTMSPRI

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: PRIMARY OUTCOME MEASURE

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: Primary Outcome Measure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C117745

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C81222

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98772
literal: Primary Outcome Measure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
abbreviated IRI: obo:ncit.owl

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: C98781

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: Intellectual Product

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: Secondary Outcome Measure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: C3274440

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: CDISC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: Secondary measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s).

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: OUTMSSEC

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: SECONDARY OUTCOME MEASURE

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: Secondary Outcome Measure

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C117745

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C61410

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66738

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C66830

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C67152

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
IRI: http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C81222

AnnotationAssertion
abbreviated IRI: obo:NCIT_C98781
literal: Secondary Outcome Measure

AnnotationAssertion
abbreviated IRI: obo:NCIT_NHC0
literal: true

AnnotationAssertion
abbreviated IRI: obo:NCIT_NHC0
literal: A property representing a concept unique identifier within the NCI Enterprise Vocabulary Service's NCI Thesaurus.

AnnotationAssertion
abbreviated IRI: obo:NCIT_NHC0
literal: NHC0

AnnotationAssertion
abbreviated IRI: obo:NCIT_NHC0
literal: code

AnnotationAssertion
abbreviated IRI: obo:NCIT_NHC0
literal: code

AnnotationAssertion
abbreviated IRI: obo:NCIT_NHC0
literal: code

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: A property that represents a description of the sort of thing or category to which a concept belongs in the context of the UMLS semantic network.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: The semantic type describes the sort of thing or category to which a concept belongs in the context of the UMLS semantic network.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: P106

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: Semantic Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: Semantic_Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: In general, applying semantic types aids in allowing users (or computer programs) to draw conclusions about concepts by virtue of the categories to which they have been assigned. We use a set of semantic types developed for the UMLS Metathesaurus. There are currently 134 semantic types in the UMLS.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: Semantic_Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_P106
literal: Semantic_Type

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: A property representing an alternative Preferred Name for use in some NCI systems.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: Provides an alternative Preferred Name for use in some NCI systems.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: P107

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: Display Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: Display_Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: Display Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: Display_Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P107
literal: Display_Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: A property representing the word or phrase that NCI uses by preference to refer to the concept.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: The word or phrase that NCI uses by preference to refer to the concept.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: P108

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: Preferred Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: Preferred_Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: Preferred Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: Preferred Term

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: Preferred_Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P108
literal: Preferred_Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P207
literal: A property representing the concept unique identifier (CUI) assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P207
literal: Concept Unique Identifiers, or CUIs, are concept numbers assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P207
literal: P207

AnnotationAssertion
abbreviated IRI: obo:NCIT_P207
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P207
literal: UMLS CUI

AnnotationAssertion
abbreviated IRI: obo:NCIT_P207
literal: UMLS_CUI

AnnotationAssertion
abbreviated IRI: obo:NCIT_P207
literal: UMLS_CUI

AnnotationAssertion
abbreviated IRI: obo:NCIT_P207
literal: UMLS_CUI

AnnotationAssertion
abbreviated IRI: obo:NCIT_P208
literal: A property representing the concept unique identifier (CUI) for those concepts that appear in NCI Metathesaurus but not in the National Library of Medicine Unified Medical Language System (NLM UMLS).

AnnotationAssertion
abbreviated IRI: obo:NCIT_P208
literal: P208

AnnotationAssertion
abbreviated IRI: obo:NCIT_P208
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P208
literal: NCI Metathesaurus CUI

AnnotationAssertion
abbreviated IRI: obo:NCIT_P208
literal: NCI_META_CUI

AnnotationAssertion
abbreviated IRI: obo:NCIT_P208
literal: NCI_META_CUI

AnnotationAssertion
abbreviated IRI: obo:NCIT_P208
literal: NCI_META_CUI

AnnotationAssertion
abbreviated IRI: obo:NCIT_P322
literal: A property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P322
literal: This property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P322
literal: P322

AnnotationAssertion
abbreviated IRI: obo:NCIT_P322
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P322
literal: Contributing Source

AnnotationAssertion
abbreviated IRI: obo:NCIT_P322
literal: Contributing_Source

AnnotationAssertion
abbreviated IRI: obo:NCIT_P322
literal: Contributing_Source

AnnotationAssertion
abbreviated IRI: obo:NCIT_P322
literal: Contributing_Source

AnnotationAssertion
abbreviated IRI: obo:NCIT_P325
literal: A property representing the English language definition of a concept from a source other than NCI.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P325
literal: English language definitions of what a source other than NCI means by the concept. These are limited to 1024 characters. They include information about the definition's source in a form that can easily be interpreted by software.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P325
literal: P325

AnnotationAssertion
abbreviated IRI: obo:NCIT_P325
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P325
literal: [source] Definition

AnnotationAssertion
abbreviated IRI: obo:NCIT_P325
literal: ALT_DEFINITION

AnnotationAssertion
abbreviated IRI: obo:NCIT_P325
literal: ALT_DEFINITION

AnnotationAssertion
abbreviated IRI: obo:NCIT_P325
literal: ALT_DEFINITION

AnnotationAssertion
abbreviated IRI: obo:NCIT_P366
literal: true

AnnotationAssertion
abbreviated IRI: obo:NCIT_P366
literal: A property representing a retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P366
literal: A retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P366
literal: P366

AnnotationAssertion
abbreviated IRI: obo:NCIT_P366
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P366
literal: Legacy Concept Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P366
literal: Legacy Concept Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P366
literal: Legacy_Concept_Name

AnnotationAssertion
abbreviated IRI: obo:NCIT_P371
literal: A property representing a term chosen by NICHD to be used in the representation of the NICHD hierarchy.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P371
literal: P371

AnnotationAssertion
abbreviated IRI: obo:NCIT_P371
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P371
literal: NICHD_Hierarchy_Term

AnnotationAssertion
abbreviated IRI: obo:NCIT_P371
literal: NICHD

AnnotationAssertion
abbreviated IRI: obo:NCIT_P371
literal: NICHD_Hierarchy_Term

AnnotationAssertion
abbreviated IRI: obo:NCIT_P371
literal: NICHD_Hierarchy_Term

AnnotationAssertion
abbreviated IRI: obo:NCIT_P375
literal: A property representing that a term in another terminology has been mapped to a term in NCIt and describes the relationship between the mapped terms.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P375
literal: P375

AnnotationAssertion
abbreviated IRI: obo:NCIT_P375
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P375
literal: Maps_To

AnnotationAssertion
abbreviated IRI: obo:NCIT_P375
literal: Maps_To

AnnotationAssertion
abbreviated IRI: obo:NCIT_P375
literal: Maps_To

AnnotationAssertion
abbreviated IRI: obo:NCIT_P98
literal: A property representing notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P98
literal: Design notes are notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept.

AnnotationAssertion
abbreviated IRI: obo:NCIT_P98
literal: P98

AnnotationAssertion
abbreviated IRI: obo:NCIT_P98
literal: Conceptual Entity

AnnotationAssertion
abbreviated IRI: obo:NCIT_P98
literal: DesignNote

AnnotationAssertion
abbreviated IRI: obo:NCIT_P98
literal: DesignNote

AnnotationAssertion
abbreviated IRI: obo:NCIT_P98
literal: DesignNote

AnnotationAssertion
abbreviated IRI: obo:NCIT_P98
literal: DesignNote

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/results_definitions.html
abbreviated IRI: obo:OAE_0000001
literal: Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant’s participation in the research, whether or not considered related to the participant’s participation in the research

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: YH: In development of OAE, we initially use vaccine adverse event as our use case. A vaccine adverse event is associated with a vaccination (i.e. a medical intervention), regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of immunization (i.e., a pharmacologic action). Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1623.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: YH: The current term 'adverse event' is different from the term definition shown in our paper: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. We made the name changing in order to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. In current definition, the adverse event emphasizes the time association and assumes a likelihood of such a causal association. This term 'adverse event' is stil under the OGMS:pathological bodily process. The 'adverse event' defined in the above paper has now been changed to a new term: 'causal adverse event'. See more information in the new publication: Yongqun He Y, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao and Barry Smith. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics. 2014, 5:29 doi:10.1186/2041-1480-5-29. PMID: 25093068.PMCID: PMC4120740.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: Yongqun He

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: AE

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: adverse reaction

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: WEB: http://en.wikipedia.org/wiki/Adverse_event

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: The OAE official website is: http://www.oae-ontology.org/.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000001
literal: adverse event

AnnotationAssertion
annotation:
  literal: https://www.clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:OAE_0000002
literal: A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
literal: medical intervention is a planned process that has the goal of diagnosing, preventing or relieving illness or injury.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
literal: The act of intervening, interfering or interceding with the intent of modifying the outcome. In medicine, an intervention is usually undertaken to help treat or cure a condition. For example, "Acupuncture as a therapeutic intervention is widely practiced in the United States," Reference: http://www.medterms.com/script/main/art.asp?articlekey=34214 . Some interventions can be used for diagnosis.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
literal: The act of intervening, interfering or interceding with the intent of modifying the outcome. In medicine, an intervention is usually undertaken to help treat or cure a condition. For example, "Acupuncture as a therapeutic intervention is widely practiced in the United States," Reference: http://www.medterms.com/script/main/art.asp?articlekey=34214 . Some interventions can be used for diagnosis.

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
literal: YH

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
literal: WEB: http://wiki.answers.com/Q/What_is_medical_intervention

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
annotation:
  literal: http://www.icmje.org/recommendations/ http://www.who.int/ictrp/network/trds/en/index.html
abbreviated IRI: obo:OAE_0000002
literal: Intervention(s)

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
literal: medical intervention

AnnotationAssertion
abbreviated IRI: obo:OAE_0000002
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:OAE_0000011
literal: a medical intervention where a patient is administered with a drug

AnnotationAssertion
abbreviated IRI: obo:OAE_0000011
literal: YH

AnnotationAssertion
abbreviated IRI: obo:OAE_0000011
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:OAE_0000011
literal: drug administration

AnnotationAssertion
abbreviated IRI: obo:OAE_0000094
literal: a medical intervention that is used for therapeutic purpose

AnnotationAssertion
abbreviated IRI: obo:OAE_0000094
literal: YH

AnnotationAssertion
abbreviated IRI: obo:OAE_0000094
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:OAE_0000094
literal: therapeutic intervention

AnnotationAssertion
abbreviated IRI: obo:OAE_0002807
literal: a medical intervention that refers to any series of pre-defined steps that should be followed to achieve a desired result.

AnnotationAssertion
abbreviated IRI: obo:OAE_0002807
literal: YH, SS

AnnotationAssertion
abbreviated IRI: obo:OAE_0002807
literal: WEB: http://www.wisegeekhealth.com/what-is-the-difference-between-a-surgery-and-a-procedure.htm

AnnotationAssertion
abbreviated IRI: obo:OAE_0002807
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:OAE_0002807
literal: medical procedure

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: planned process

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: planned process

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: Injecting mice with a vaccine in order to test its efficacy

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: A processual entity that realizes a plan which is the concretization of a plan specification.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: 'Plan' includes a future direction sense. That can be problematic if plans are changed during their execution. There are however implicit contingencies for protocols that an agent has in his mind that can be considered part of the plan, even if the agent didn't have them in mind before. Therefore, a planned process can diverge from what the agent would have said the plan was before executing it, by adjusting to problems encountered during execution (e.g. choosing another reagent with equivalent properties, if the originally planned one has run out.)

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some objectives is a planned process.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some objectives is a planned process.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: branch derived

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: 6/11/9: Edited at workshop. Used to include: is initiated by an agent

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: This class merges the previously separated objective driven process and planned process, as they the separation proved hard to maintain. (1/22/09, branch call)

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:dron.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:envo.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:ico.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
abbreviated IRI: obo:vo.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: http://purl.obolibrary.org/obo/obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: planned process

AnnotationAssertion
abbreviated IRI: obo:OBI_0000011
literal: planned process

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: investigation

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: Lung cancer investigation using expression profiling, a stem cell transplant investigation, biobanking is not an investigation, though it may be part of an investigation

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: a planned process that consists of parts: planning, study design execution, documentation and which produce conclusion(s).

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: OBI branch derived

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: Could add specific objective specification

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: Following OBI call November 2012,26th: it was decided there was no need for adding "achieves objective of drawing conclusion" as existing relations were providing equivalent ability. this note closes the issue and validates the class definition to be part of the OBI core editor = PRS

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: study

AnnotationAssertion
abbreviated IRI: obo:OBI_0000066
literal: investigation

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: assay

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: Assay the wavelength of light emitted by excited Neon atoms. Count of geese flying over a house.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: 12/3/12: BP: the reference to the 'physical examination' is included to point out that a prediction is not an assay, as that does not require physical examiniation.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: PlanAndPlannedProcess Branch

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: measuring

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: scientific observation

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: OBI branch derived

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: study assay

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: any method

AnnotationAssertion
abbreviated IRI: obo:OBI_0000070
literal: assay

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
literal: responsible party role

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
literal: he THERAPIST has the ability to print a separate statement for the patient and each responsible party. http://www.beaverlog.com/therapist/ez_support/billing/responsible_party_statements.htm

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
literal: a study personnel role played by a party who is accountable for the execution of a study component and can make decisions about the conduct of the study

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
literal: Person: Jennifer Fostel

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
literal: responsible party

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
literal: OBI

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000102
literal: responsible party role

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
literal: intervention design

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
literal: PMID: 18208636.Br J Nutr. 2008 Jan 22;:1-11.Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention study.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OBI_0000115
literal: A description of the manner in which the clinical trial will be conducted.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
literal: An intervention design is a study design in which a controlled process applied to the subjects (the intervention) serves as the independent variable manipulated by the experimentalist. The treatment (perturbation or intervention) defined can be defined as a combination of values taken by independent variable manipulated by the experimentalists are applied to the recruited subjects assigned (possibly by applying specific methods) to treatment groups. The specificity of intervention design is the fact that independent variables are being manipulated and a response of the biological system is evaluated via response variables as monitored by possibly a series of assays.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
literal: Philppe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
literal: OBI branch derived

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
literal: Interventional Study Design

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
literal: intervention model

AnnotationAssertion
abbreviated IRI: obo:OBI_0000115
literal: intervention design

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: investigation agent role

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: The person perform microarray experiments and submit microarray results (including raw data, processed data) with experiment description to ArrayExpress.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: A role borne by an entity and that is realized in a process that is part of an investigation in which an objective is achieved. These processes include, among others: planning, overseeing, funding, reviewing.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: Implementing a study means carrying out or performing the study and providing reagents or other materials used in the study and other tasks without which the study would not happen.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: Philly2013: Historically, this role would have been borne only by humans or organizations. However, we now also want to enable representing investigations run by robot scientists such as ADAM (King et al, Science, 2009)

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: GROUP: Role Branch

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: investigator

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: OBI

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: Feb 10, 2009. changes after discussion at OBI Consortium Workshop Feb 2-6, 2009. accepted as core term.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: study person role

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: Philly2013: Historically, this role would have been borne only by humans or organizations. However, we now also want to enable investigations run by robot scientists such as ADAM (King et al, Science, 2009)

AnnotationAssertion
abbreviated IRI: obo:OBI_0000202
literal: investigation agent role

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
literal: sponsor role

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
literal: a responsible party role involved with any of the following activities: initiating, managing and funding a study

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
literal: Person: Jennifer Fostel

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
literal: sponsor

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
literal: CDISC definition: sponsor. 1. An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. 2. A corporation or agency whose employees conduct the investigation is considered a sponsor; employees are considered investigators

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000243
literal: sponsor role

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: organization

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: PMID: 16353909.AAPS J. 2005 Sep 22;7(2):E274-80. Review. The joint food and agriculture organization of the United Nations/World Health Organization Expert Committee on Food Additives and its role in the evaluation of the safety of veterinary drug residues in foods.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: An entity that can bear roles, has members, and has a set of organization rules. Members of organizations are either organizations themselves or individual people. Members can bear specific organization member roles that are determined in the organization rules. The organization rules also determine how decisions are made on behalf of the organization by the organization members.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: BP: The definition summarizes long email discussions on the OBI developer, roles, biomaterial and denrie branches. It leaves open if an organization is a material entity or a dependent continuant, as no consensus was reached on that. The current placement as material is therefore temporary, in order to move forward with development. Here is the entire email summary, on which the definition is based: 1) there are organization_member_roles (president, treasurer, branch editor), with individual persons as bearers 2) there are organization_roles (employer, owner, vendor, patent holder) 3) an organization has a charter / rules / bylaws, which specify what roles there are, how they should be realized, and how to modify the charter/rules/bylaws themselves. It is debatable what the organization itself is (some kind of dependent continuant or an aggregate of people). This also determines who/what the bearer of organization_roles' are. My personal favorite is still to define organization as a kind of 'legal entity', but thinking it through leads to all kinds of questions that are clearly outside the scope of OBI. Interestingly enough, it does not seem to matter much where we place organization itself, as long as we can subclass it (University, Corporation, Government Agency, Hospital), instantiate it (Affymetrix, NCBI, NIH, ISO, W3C, University of Oklahoma), and have it play roles. This leads to my proposal: We define organization through the statements 1 - 3 above, but without an 'is a' statement for now. We can leave it in its current place in the is_a hierarchy (material entity) or move it up to 'continuant'. We leave further clarifications to BFO, and close this issue for now.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: PERSON: Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: PERSON: Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: PERSON: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: PERSON: Susanna Sansone

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: GROUP: OBI

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000245
literal: organization

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
literal: protocol

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
literal: PCR protocol, has objective specification, amplify DNA fragment of interest, and has action specification describes the amounts of experimental reagents used (e..g. buffers, dNTPS, enzyme), and the temperature and cycle time settings for running the PCR.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
literal: A plan specification which has sufficient level of detail and quantitative information to communicate it between investigation agents, so that different investigation agents will reliably be able to independently reproduce the process.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
literal: PlanAndPlannedProcess Branch

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
literal: OBI branch derived + wikipedia (http://en.wikipedia.org/wiki/Protocol_%28natural_sciences%29)

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
literal: study protocol

AnnotationAssertion
abbreviated IRI: obo:OBI_0000272
literal: protocol

AnnotationAssertion
abbreviated IRI: obo:OBI_0000293
literal: has_specified_input

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
literal: informed consent process

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
literal: A planned process in which a person or their legal representative is informed about key facts about potential risks and benefits of a process and makes a documented decision as to whether the person in question will participate.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
literal: 09/28/2009 Alan Ruttenberg: This is made a subclass of the higher level processual entity in BFO because I don't want to take a stand on whether it is a process aggregate. Analogous to the situation with Material entity.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
literal: Person:Alan Ruttenberg

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
literal: http://clinicaltrials.gov/ct2/info/glossary#informed

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
literal: 2009/09/28 Alan Ruttenberg. Fucoidan-use-case

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000810
literal: informed consent process

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: device

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: A voltmeter is a measurement device which is intended to perform some measure function.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: An autoclave is a device that sterlizes instruments or contaminated waste by applying high temperature and pressure.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: A material entity that is designed to perform a function in a scientific investigation, but is not a reagent.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: 2012-12-17 JAO: In common lab usage, there is a distinction made between devices and reagents that is difficult to model. Therefore we have chosen to specifically exclude reagents from the definition of "device", and are enumerating the types of roles that a reagent can perform. 2013-6-5 MHB: The following clarifications are outcomes of the May 2013 Philly Workshop. Reagents are distinguished from devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in some chemical interaction or reaction during the realization of their experimental role. By contrast, devices do not participate in such chemical reactions/interactions. Note that there are cases where devices use reagent components during their operation, where the reagent-device distinction is less clear. For example: (1) An HPLC machine is considered a device, but has a column that holds a stationary phase resin as an operational component. This resin qualifies as a device if it participates purely in size exclusion, but bears a reagent role that is realized in the running of a column if it interacts electrostatically or chemically with the evaluant. The container the resin is in (“the column”) considered alone is a device. So the entire column as well as the entire HPLC machine are devices that have a reagent as an operating part. (2) A pH meter is a device, but its electrode component bears a reagent role in virtue of its interacting directly with the evaluant in execution of an assay. (3) A gel running box is a device that has a metallic lead as a component that participates in a chemical reaction with the running buffer when a charge is passed through it. This metallic lead is considered to have a reagent role as a component of this device realized in the running of a gel. In the examples above, a reagent is an operational component of a device, but the device itself does not realize a reagent role (as bearing a reagent…

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: PERSON: Helen Parkinson

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: instrument

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: OBI development call 2012-12-17.

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0000968
literal: device

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
literal: country name

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
literal: A textual entity that denotes a geographic location that is a site or part of a site that is identified as a country in the political geography.

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
literal: Person: Chris Stoeckert, Jie Zheng

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
literal: NIAID GSCID-BRC metadata working group

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
literal: Website: http://en.wikipedia.org/wiki/Country

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
literal: Specimen Collection Location - Country

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
literal: NIAID GSCID-BRC

AnnotationAssertion
abbreviated IRI: obo:OBI_0001627
literal: country name

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
literal: selection criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
literal: rats should be aged between 6 and 8 weeks and weight between 180-250grams

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
literal: A directive information entity which defines and states a principle of standard by which selection process may take place.

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
literal: Person: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
literal: selection rule

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
literal: OBI discussion summarized under the following tracker item : http://sourceforge.net/p/obi/obi-terms/678/

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0001755
literal: selection criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0001847
literal: ISA alternative term

AnnotationAssertion
abbreviated IRI: obo:OBI_0001847
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0001847
literal: An alternative term used by the ISA tools project (http://isa-tools.org).

AnnotationAssertion
abbreviated IRI: obo:OBI_0001847
literal: Requested by Alejandra Gonzalez-Beltran https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891&atid=886178

AnnotationAssertion
abbreviated IRI: obo:OBI_0001847
literal: Person: Alejandra Gonzalez-Beltran

AnnotationAssertion
abbreviated IRI: obo:OBI_0001847
literal: Person: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0001847
literal: ISA tools project (http://isa-tools.org)

AnnotationAssertion
abbreviated IRI: obo:OBI_0001847
literal: ISA alternative term

AnnotationAssertion
abbreviated IRI: obo:OBI_0001886
literal: NIAID GSCID-BRC alternative term

AnnotationAssertion
abbreviated IRI: obo:OBI_0001886
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0001886
literal: An alternative term used by the National Institute of Allergy and Infectious Diseases (NIAID) Genomic Sequencing Centers for Infectious Diseases (GSCID) and Bioinformatics Resource Centers (BRC).

AnnotationAssertion
abbreviated IRI: obo:OBI_0001886
literal: PERSON: Chris Stoeckert, Jie Zheng

AnnotationAssertion
abbreviated IRI: obo:OBI_0001886
literal: NIAID GSCID-BRC metadata working group

AnnotationAssertion
abbreviated IRI: obo:OBI_0001886
literal: NIAID GSCID-BRC alternative term

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
literal: selection

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
literal: PMID: 24023800. In this study, a set of eleven genes (VATP16, 60 S, UQCC, SMD3, EF1α, UBQ, SAND, GAPDH, ACT, PsaB, PTB2) was evaluated to identify reference genes during the first hours of interaction (6, 12, 18 and 24 hpi) between two V. vinifera genotypes and P. viticola. Two analyses were used for the selection of reference genes: direct comparison of susceptible, Trincadeira, and resistant, Regent, V. vinifera cultivars at 0 h, 6, 12, 18 and 24 hours post inoculation with P. viticola (genotype effect); and comparison of each genotype with mock inoculated samples during inoculation time-course (biotic stress effect). Three statistical methods were used, GeNorm, NormFinder, and BestKeeper, allowing to identify UBQ, EF1α and GAPDH as the most stable genes for the genotype effect.

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
literal: A planned process which results in the creation of group of entity from a larger group by the application of predefined criteria.

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
literal: this term refers to a planned process and therefore is distinct from the notion of 'natural selection', a process covering the operation of natural causes by which those individuals of a species that are best adapted to the environment tend to be preserved and to transmit their characters, while those less adapted die out, so that in the course of generations the degree of adaptation to the environment tends progressively to increase. (as defined by Oxford English Dictionary)

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
literal: Person: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
literal: selection process

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
literal: OBI

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0001928
literal: selection

AnnotationAssertion
abbreviated IRI: obo:OBI_0001933
literal: value specification

AnnotationAssertion
abbreviated IRI: obo:OBI_0001933
literal: The value of 'positive' in a classification scheme of "positive or negative"; the value of '20g' on the quantitative scale of mass.

AnnotationAssertion
abbreviated IRI: obo:OBI_0001933
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0001933
literal: An information content entity that specifies a value within a classification scheme or on a quantitative scale.

AnnotationAssertion
abbreviated IRI: obo:OBI_0001933
literal: This term is currently a descendant of 'information content entity', which requires that it 'is about' something. A value specification of '20g' for a measurement data item of the mass of a particular mouse 'is about' the mass of that mouse. However there are cases where a value specification is not clearly about any particular. In the future we may change 'value specification' to remove the 'is about' requirement.

AnnotationAssertion
abbreviated IRI: obo:OBI_0001933
literal: PERSON:Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:OBI_0001933
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0001933
literal: value specification

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
literal: age group inclusion criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
literal: "18-33 years old"

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:OBI_0002555
literal: A type of eligibility criteria that indicates the age a person must be to participate in a clinical study. This may be indicated by a specific age or the following age groups. The age groups are: Child (birth-17), Adult (18-64), Older Adult (65+).

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
literal: An inclusion criterion that defines and states an age bracket which, if met, makes an entity suitable for a given task or participation in a given process.

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
literal: Mathias Brochhausen

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
literal: #839

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
literal: ages eligible for study

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
literal: age group inclusion criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0002555
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:OBI_0002556
literal: minimum age value specification

AnnotationAssertion
abbreviated IRI: obo:OBI_0002556
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
abbreviated IRI: obo:OBI_0002556
literal: A value specifcation that specifies the youngest age when specifying an age range.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OBI_0002556
literal: The numerical value, if any, for the minimum age a potential participant must meet to be eligible for the clinical study.

AnnotationAssertion
abbreviated IRI: obo:OBI_0002556
literal: Mathias Brochhausen

AnnotationAssertion
abbreviated IRI: obo:OBI_0002556
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0002556
literal: minimum age

AnnotationAssertion
abbreviated IRI: obo:OBI_0002556
literal: minimum age value specification

AnnotationAssertion
abbreviated IRI: obo:OBI_0002557
literal: maximum age value specification

AnnotationAssertion
abbreviated IRI: obo:OBI_0002557
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
abbreviated IRI: obo:OBI_0002557
literal: A value specifcation that specifies the oldest age when specifying an age range.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OBI_0002557
literal: The numerical value, if any, for the maximum age a potential participant can be to be eligible for the clinical study.

AnnotationAssertion
abbreviated IRI: obo:OBI_0002557
literal: Mathias Brochhausen

AnnotationAssertion
abbreviated IRI: obo:OBI_0002557
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0002557
literal: maximum age

AnnotationAssertion
abbreviated IRI: obo:OBI_0002557
literal: maximum age value specification

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
literal: sex inclusion criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
literal: "included males and females", "included male patients"

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:OBI_0002561
literal: A type of eligibility criteria that indicates the sex of people who may participate in a clinical study (all, female, male). Sex is a person's classification as female or male based on biological distinctions. Sex is distinct from gender-based eligibility.

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
literal: An inclusion criterion that defines and states one or more sexes which, if met, makes an entity suitable for a given task or participation in a given process.

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
literal: Mathias Brochhausen

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
literal: sexes eligible for study

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
literal: sex inclusion criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0002561
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:OBI_0002624
literal: case-control study design

AnnotationAssertion
abbreviated IRI: obo:OBI_0002624
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:OBI_0002624
literal: A study design that entails the creation of two types of roles, such that each participant under investigation bears one or the other. What distinguishes the two types of roles is an 'outcome', which is associated with participants that have the case role but not associated with participants that have the control role. A case-control study examines the hypothesis that the presence of the outcome in case participants is associated with an 'exposure' that is not associated with control participants.

AnnotationAssertion
abbreviated IRI: obo:OBI_0002624
literal: John Judkins, Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:OBI_0002624
literal: Wikipedia, OBI

AnnotationAssertion
abbreviated IRI: obo:OBI_0002624
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0002624
literal: case-control study design

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
literal: observation design

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
literal: PMID: 12387964.Lancet. 2002 Oct 12;360(9340):1144-9.Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study.

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
literal: observation design is a study design in which subjects are monitored in the absence of any active intervention by experimentalists.

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
literal: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
literal: OBI branch derived

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
literal: observation design

AnnotationAssertion
abbreviated IRI: obo:OBI_0300311
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: study design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: a matched pairs study design describes criteria by which subjects are identified as pairs which then undergo the same protocols, and the data generated is analyzed by comparing the differences between the paired subjects, which constitute the results of the executed study design.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: A plan specification comprised of protocols (which may specify how and what kinds of data will be gathered) that are executed as part of an investigation and is realized during a study design execution.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: Editor note: there is at least an implicit restriction on the kind of data transformations that can be done based on the measured data available.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: PERSON: Chris Stoeckert

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: experimental design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: rediscussed at length (MC/JF/BP). 12/9/08). The definition was clarified to differentiate it from protocol.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
abbreviated IRI: obo:omiabis.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: study design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:OBI_0500000
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:OBI_0500002
literal: repeated measure design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500002
literal: PMID: 10959922.J Biopharm Stat. 2000 Aug;10(3):433-45.Equivalence in test assay method comparisons for the repeated-measure, matched-pair design in medical device studies: statistical considerations.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500002
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
abbreviated IRI: obo:OBI_0500002
literal: a study design which use the same individuals and exposure them to a set of conditions. The effect of order and practice can be confounding factor in such designs

AnnotationAssertion
abbreviated IRI: obo:OBI_0500002
literal: PlanAndPlannedProcess Branch

AnnotationAssertion
abbreviated IRI: obo:OBI_0500002
literal: http://www.holah.karoo.net/experimentaldesigns.htm

AnnotationAssertion
abbreviated IRI: obo:OBI_0500002
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0500002
literal: repeated measure design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500003
literal: cross over design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500003
literal: PMID: 17601993-Objective: HIV-infected patients with lipodystrophy (HIV-lipodystrophy) are insulin resistant and have elevated plasma free fatty acid (FFA) concentrations. We aimed to explore the mechanisms underlying FFA-induced insulin resistance in patients with HIV-lipodystrophy. Research Design and Methods: Using a randomized placebo-controlled cross-over design, we studied the effects of an overnight acipimox-induced suppression of FFA on glucose and FFA metabolism by using stable isotope labelled tracer techniques during basal conditions and a two-stage euglycemic, hyperinsulinemic clamp (20 mU insulin/m(2)/min; 50 mU insulin/m(2)/min) in nine patients with nondiabetic HIV-lipodystrophy. All patients received antiretroviral therapy. Biopsies from the vastus lateralis muscle were obtained during each stage of the clamp. Results: Acipimox treatment reduced basal FFA rate of appearance by 68.9% (52.6%-79.5%) and decreased plasma FFA concentration by 51.6 % (42.0%-58.9%), (both, P < 0.0001). Endogenous glucose production was not influenced by acipimox. During the clamp the increase in glucose-uptake was significantly greater after acipimox treatment compared to placebo (acipimox: 26.85 (18.09-39.86) vs placebo: 20.30 (13.67-30.13) mumol/kg/min; P < 0.01). Insulin increased phosphorylation of Akt (Thr(308)) and GSK-3beta (Ser(9)), decreased phosphorylation of glycogen synthase (GS) site 3a+b and increased GS-activity (I-form) in skeletal muscle (P < 0.01). Acipimox decreased phosphorylation of GS (site 3a+b) (P < 0.02) and increased GS-activity (P < 0.01) in muscle. Conclusion: The present study provides direct evidence that suppression of lipolysis in patients with HIV-lipodystrophy improves insulin-stimulated peripheral glucose-uptake. The increased glucose-uptake may in part be explained by increased dephosphorylation of GS (site 3a+b) resulting in increased GS activity.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500003
abbreviated IRI: obo:IAO_0000120

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OBI_0500003
literal: Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study

AnnotationAssertion
abbreviated IRI: obo:OBI_0500003
literal: a repeated measure design which ensures that experimental units receive, in sequence, the treatment (or the control), and then, after a specified time interval (aka *wash-out periods*), switch to the control (or treatment). In this design, subjects (patients in human context) serve as their own controls, and randomization may be used to determine the ordering which a subject receives the treatment and control

AnnotationAssertion
abbreviated IRI: obo:OBI_0500003
literal: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0500003
literal: (source: http://www.sbu.se/Filer/Content0/publikationer/1/literaturesearching_1993/glossary.html)

AnnotationAssertion
abbreviated IRI: obo:OBI_0500003
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0500003
literal: cross over design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500004
literal: n-to-1 design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500004
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:OBI_0500004
literal: N-of-1 design is a cross-over design in which the same patient is repeatedly randomised to receive either the experimental treatment or its control (Senn, 1993).

AnnotationAssertion
abbreviated IRI: obo:OBI_0500004
literal: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0500004
literal: Adapted from http://www.childrens-mercy.org/stats/definitions/crossover.htm and source:http://symptomresearch.nih.gov/chapter_6/sec1/csss1pg1.htm)

AnnotationAssertion
abbreviated IRI: obo:OBI_0500004
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0500004
literal: n-to-1 design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
literal: parallel group design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
literal: PMID: 17408389-Purpose: Proliferative vitreoretinopathy (PVR) is the most important reason for blindness following retinal detachment. Presently, vitreous tamponades such as gas or silicone oil cannot contact the lower part of the retina. A heavier-than-water tamponade displaces the inflammatory and PVR-stimulating environment from the inferior area of the retina. The Heavy Silicone Oil versus Standard Silicone Oil Study (HSO Study) is designed to answer the question of whether a heavier-than-water tamponade improves the prognosis of eyes with PVR of the lower retina. Methods: The HSO Study is a multicentre, randomized, prospective controlled clinical trial comparing two endotamponades within a two-arm parallel group design. Patients with inferiorly and posteriorly located PVR are randomized to either heavy silicone oil or standard silicone oil as a tamponading agent. Three hundred and fifty consecutive patients are recruited per group. After intraoperative re-attachment, patients are randomized to either standard silicone oil (1000 cSt or 5000 cSt) or Densiron((R)) as a tamponading agent. The main endpoint criteria are complete retinal attachment at 12 months and change of visual acuity (VA) 12 months postoperatively compared with the preoperative VA. Secondary endpoints include complete retinal attachment before endotamponade removal, quality of life analysis and the number of retina affecting re-operation within 1 year of follow-up. Results: The design and early recruitment phase of the study are described. Conclusions: The results of this study will uncover whether or not heavy silicone oil improves the prognosis of eyes with PVR.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
literal: A parallel group design or independent measure design is a study design which uses unique experimental unit each experimental group, in other word no two individuals are shared between experimental groups, hence also known as parallel group design. Subjects of a treatment group receive a unique combination of independent variable values making up a treatment

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OBI_0500006
literal: Participants are assigned to one of two or more groups in parallel for the duration of the study

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
literal: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
literal: independent measure design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
literal: http://www.holah.karoo.net/experimentaldesigns.htm

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0500006
literal: parallel group design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500014
literal: factorial design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500014
literal: PMID: 17582121-Our objective was to examine the effects of dietary cation-anion difference (DCAD) with different concentrations of dietary crude protein (CP) on performance and acid-base status in early lactation cows. Six lactating Holstein cows averaging 44 d in milk were used in a 6 x 6 Latin square design with a 2 x 3 factorial arrangement of treatments: DCAD of -3, 22, or 47 milliequivalents (Na + K - Cl - S)/100 g of dry matter (DM), and 16 or 19% CP on a DM basis. Linear increases with DCAD occurred in DM intake, milk fat percentage, 4% fat-corrected milk production, milk true protein, milk lactose, and milk solids-not-fat. Milk production itself was unaffected by DCAD. Jugular venous blood pH, base excess and HCO3(-) concentration, and urine pH increased, but jugular venous blood Cl- concentration, urine titratable acidity, and net acid excretion decreased linearly with increasing DCAD. An elevated ratio of coccygeal venous plasma essential AA to nonessential AA with increasing DCAD indicated that N metabolism in the rumen was affected, probably resulting in more microbial protein flowing to the small intestine. Cows fed 16% CP had lower urea N in milk than cows fed 19% CP; the same was true for urea N in coccygeal venous plasma and urine. Dry matter intake, milk production, milk composition, and acid-base status did not differ between the 16 and 19% CP treatments. It was concluded that DCAD affected DM intake and performance of dairy cows in early lactation. Feeding 16% dietary CP to cows in early lactation, compared with 19% CP, maintained lactation performance while reducing urea N excretion in milk and urine.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500014
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OBI_0500014
literal: Two or more interventions, each alone and in combination, are evaluated in parallel against a control group

AnnotationAssertion
abbreviated IRI: obo:OBI_0500014
literal: factorial design is_a study design which is used to evaluate two or more factors simultaneously. The treatments are combinations of levels of the factors. The advantages of factorial designs over one-factor-at-a-time experiments is that they are more efficient and they allow interactions to be detected. In statistics, a factorial design experiment is an experiment whose design consists of two or more factors, each with discrete possible values or levels, and whose experimental units take on all possible combinations of these levels across all such factors. Such an experiment allows studying the effect of each factor on the response variable, as well as the effects of interactions between factors on the response variable.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500014
literal: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0500014
literal: http://www.stats.gla.ac.uk/steps/glossary/anova.html#facdes And from wikipedia (01/03/2007): http://en.wikipedia.org/wiki/Factorial_experiment)

AnnotationAssertion
abbreviated IRI: obo:OBI_0500014
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0500014
literal: factorial design

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
literal: eligibility criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
literal: PMID: 17579629 -Eligibility criteria included: untreated ED-SCLC; age >/=70 and performance status 0-2, or age <70 and PS 3.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OBI_0500026
literal: A limited list of criteria for selection of participants in the clinical study, provided in terms of inclusion and exclusion criteria and suitable for assisting potential participants in identifying clinical studies of interest.

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:OBI_0500026
literal: The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
literal: an eligibility criterion (rule) is_a selection criterion which defines and states the requirements (positive or negative) for an entity to be considered as suitable for a given task or participation in a process.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
literal: Person: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
literal: eligibility rule

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
literal: Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0500026
literal: eligibility criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
literal: inclusion criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
literal: PMID: 23979341-The major inclusion criterion was patients in whom severe cerebral embolism was diagnosed at age 75 or younger (more than 9 in the NIHSS score on day 7 after the onset of stroke) .

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:OBI_0500027
literal: A type of eligibility criteria. These are the reasons that a person is allowed to participate in a clinical study.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
literal: an inclusion criterion (rule) is_a *eligibility criterion* which defines and states a condition which, if met, makes an entity suitable for a given task or participation in a given process. For instance, in a study protocol, inclusion criteria indicate the conditions that prospective subjects MUST meet to be eligible for participation in a study.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
literal: Person: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
literal: inclusion condition

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
literal: inclusion rule

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
literal: Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
abbreviated IRI: obo:obi.owl

AnnotationAssertion
annotation:
  literal: http://www.icmje.org/recommendations/ https://www.who.int/ictrp/network/trds/en/
abbreviated IRI: obo:OBI_0500027
literal: key inclusion criteria

AnnotationAssertion
abbreviated IRI: obo:OBI_0500027
literal: inclusion criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0500028
literal: exclusion rule

AnnotationAssertion
abbreviated IRI: obo:OBI_0500028
literal: PMID: 17600285-Exclusion criteria included the use of any topical ophthalmic or topical oral medication and/or history of ocular or oral surgery within the past six months.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500028
abbreviated IRI: obo:IAO_0000125

AnnotationAssertion
annotation:
  literal: https://clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:OBI_0500028
literal: A type of eligibility criteria. These are reasons that a person is not allowed to participate in a clinical study.

AnnotationAssertion
abbreviated IRI: obo:OBI_0500028
literal: an exclusion criterion (rule) is_a *eligibility criterion* which defines and states a condition which, if met, makes an entity unsuitable for a given task or participation in a given process. For instance, in a study protocol, exclusion criteria indicate the conditions that prospective subjects SHOULD NOT meet to be eligible for participation in a study

AnnotationAssertion
abbreviated IRI: obo:OBI_0500028
literal: Person: Philippe Rocca-Serra

AnnotationAssertion
abbreviated IRI: obo:OBI_0500028
literal: Adapted from Clinical Research Glossary Version 4.0 CDICS glossary group

AnnotationAssertion
abbreviated IRI: obo:OBI_0500028
abbreviated IRI: obo:obi.owl

AnnotationAssertion
annotation:
  literal: http://www.icmje.org/recommendations/ https://www.who.int/ictrp/network/trds/en/
abbreviated IRI: obo:OBI_0500028
literal: key exclusion criteria

AnnotationAssertion
abbreviated IRI: obo:OBI_0500028
literal: exclusion criterion

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
literal: human subject enrollment

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
literal: enlisting familiy members of HIV patients into a study

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
literal: A planned process with the objective to obtain a population of human subjects to participate in an investigation by determining eligibility of subjects and obtaining informed consent.

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
literal: As with group assignment, should the specified output here be an organism which bears a role

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
literal: Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
literal: IEDB

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
literal: criteria come from plan / clinical trial branch

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:OBI_0600004
literal: human subject enrollment

AnnotationAssertion
abbreviated IRI: obo:OBI_9991118
literal: IEDB alternative term

AnnotationAssertion
abbreviated IRI: obo:OBI_9991118
abbreviated IRI: obo:IAO_0000122

AnnotationAssertion
abbreviated IRI: obo:OBI_9991118
literal: An alternative term used by the IEDB.

AnnotationAssertion
abbreviated IRI: obo:OBI_9991118
literal: PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters

AnnotationAssertion
abbreviated IRI: obo:OBI_9991118
literal: IEDB

AnnotationAssertion
abbreviated IRI: obo:OBI_9991118
literal: IEDB alternative term

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000014
literal: A representation that is either the output of a clinical history taking or a physical examination or an image finding, or some combination thereof.

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000014
literal: Albert Goldfain

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000014
literal: http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000014
literal: creation date: 2010-07-19T10:18:02Z

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000014
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000014
literal: clinical finding

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000015
literal: A series of statements representing health-relevant qualities of a patient and of a patient's family.

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000015
literal: Albert Goldfain

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000015
literal: http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000015
literal: creation date: 2010-07-19T10:18:59Z

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000015
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000015
literal: clinical history

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000019
literal: A representation of a quality of a patient that is (1) recorded by a clinician because the quality is hypothesized to be of clinical significance and (2) refers to qualities obtaining in the patient prior to their becoming detectable in a clinical history taking or physical examination.

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000019
literal: Albert Goldfain

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000019
literal: http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000019
literal: creation date: 2009-06-23T10:22:44Z

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000019
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000019
literal: preclinical finding

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000031
literal: A disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism.

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000031
literal: Albert Goldfain

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000031
literal: http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000031
literal: creation date: 2009-06-23T11:21:20Z

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000031
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000031
literal: disease

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000060
literal: Albert Goldfain

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000060
literal: creation date: 2009-06-23T11:53:49Z

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000060
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000060
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000060
literal: bodily process

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000061
literal: A bodily process that is clinically abnormal.

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000061
literal: Albert Goldfain

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000061
literal: http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000061
literal: creation date: 2009-06-23T11:54:29Z

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000061
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000061
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000061
literal: pathological bodily process

AnnotationAssertion
annotation:
  literal: https://www.clinicaltrialsregister.eu/doc/EU_Clinical_Trials_Register_Glossary.pdf
abbreviated IRI: obo:OGMS_0000073
literal: 1. the determination of the nature of a case of disease. 2. the art of distinguishing one disease from another.

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000073
literal: The representation of a conclusion of a diagnostic process.

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000073
literal: Albert Goldfain

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000073
literal: http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000073
literal: creation date: 2009-06-23T12:42:23Z

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000073
abbreviated IRI: obo:ogms.owl

AnnotationAssertion
abbreviated IRI: obo:OGMS_0000073
literal: diagnosis

AnnotationAssertion
abbreviated IRI: obo:OMIABIS_0001019
literal: A study design that involves repeated observations of the same entity over time. In the biobank context, longitudinal studies sample a group of people in a given time period, and study them at intervals by the acquisition and analyses of data and/or samples over time.

AnnotationAssertion
abbreviated IRI: obo:OMIABIS_0001019
literal: Alice Nzinga

AnnotationAssertion
abbreviated IRI: obo:OMIABIS_0001019
abbreviated IRI: obo:omiabis.owl

AnnotationAssertion
abbreviated IRI: obo:OMIABIS_0001019
literal: longitudinal study design

AnnotationAssertion
abbreviated IRI: obo:OMIABIS_0001020
literal: A longitudinal study that aims to study a case-defined population who presently have a certain condition or recepient of a particular treatment that are followed over time and are compared with a similar group who do not have condition.

AnnotationAssertion
abbreviated IRI: obo:OMIABIS_0001020
abbreviated IRI: obo:omiabis.owl

AnnotationAssertion
abbreviated IRI: obo:OMIABIS_0001020
literal: cohort study design

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000024
literal: A role inhering in an entity realized by social interactions in human society.

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000024
literal: Mathias Brochhausen

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000024
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000024
literal: Previous definition: A role played by an entity in human social processes.

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000024
literal: role in human social processes

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000038
literal: A role borne by a human individual or by a collection of humans regarded as possessing rights and duties enforeable at law.

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000038
literal: Mathias Brochhausen

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000038
literal: Malcolm N. Shaw: International Law. Cambridge University Press, Cambridge, 2008.

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000038
abbreviated IRI: obo:omrse.owl

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000038
literal: We are aware of the fact that Wikipedia's definition differs from ours by saying that "Legal personality (...) is the characteristic of a non-living entity regarded by law to have the status of personhood" (http://en.wikipedia.org/wiki/Legal_personality) However, Shaw explicates: "In any legal system, certain entities, whether they be individuals or companies, will be regarded as possessing rights and duties enforceable at law. Thus an individual may prosecute or be prosecuted for assault and a company can sue for breach of contract. They are able to do this because the law recognises them as 'legal persons' possessing the capacity to have and to maintain certain rights, and being subject to perform specific duties. (...) In municipal law individuals, limited companies and public corporations are recognized as each possessing a distinct legal personality, the terms of which are circumscribed by the relevant legislation" (Shaw MN: International Law. Sixth Edition. Cambridge University Press, Cambridge, 2008). We hold that Shaw's position is ontological more prolific since it not only allows to explain how groups of individuals become recognized as unities at law, but also how different individuals can hold different legal personality roles (always against the context of one legal system). The latter will proof useful when dealing with the representing comatous patients or minorsat law in ontologies.

AnnotationAssertion
abbreviated IRI: obo:OMRSE_00000038
literal: legal person role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000112
literal: A telephone number is a sequence of digits assigned to a fixed-line telephone subscriber station connected to a telephone line or to a wireless electronic telephony device, such as a radio telephone or a mobile telephone, or to other devices for data transmission via the public switched telephone network (PSTN) or other public and private networks.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000112
literal: Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000112
literal: phone number

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000112
literal: https://en.wikipedia.org/wiki/Telephone_number

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000112
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000112
literal: telephone number

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000223
literal: The textual name of the contact person or organization

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000223
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000223
literal: contact name

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000282
literal: The medical state or condition of a patient

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000282
literal: Oliver He, Edison Ong

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000282
literal: medical state

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000282
literal: https://en.wikipedia.org/wiki/Medical_state

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000282
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000282
literal: medical condition

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000293
literal: A person who performs an investigation task and takes the role of an investigator role.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000293
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000293
literal: investigator

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000294
literal: An investigator who is involved in a clinical trial and is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations; for protecting the rights, safety, and welfare of subjects under the investigator's care; and for the control of drugs under investigation.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000294
literal: Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000294
literal: https://en.wikipedia.org/wiki/Clinical_investigator

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000294
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000294
literal: clinical investigator

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000296
literal: The (estimated) date on which the clinical study is open for recruitment of participants, or the actual date on which the first participant is enrolled.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000296
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000296
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
annotation:
  literal: http://www.icmje.org/recommendations/ http://www.who.int/ictrp/network/trds/en/index.html
abbreviated IRI: obo:OPMI_0000296
literal: date of first enrollment

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000296
literal: study start

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000296
literal: clinical trial start date

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000297
literal: The date on which a study completes

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OPMI_0000297
literal: The date the final participant was examined or received an intervention for purposes of final collection of data for the primary and secondary outcome measures and adverse events (for example, last participant’s last visit), whether the clinical study concluded according to the pre-specified protocol or was terminated.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000297
literal: Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000297
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
annotation:
  literal: http://www.icmje.org/recommendations/ http://www.who.int/ictrp/network/trds/en/index.html
abbreviated IRI: obo:OPMI_0000297
literal: Completion Date

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000297
literal: study completion

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000297
literal: study completion date

AnnotationAssertion
annotation:
  literal: https://www.clinicaltrials.gov/ct2/about-studies/glossary
abbreviated IRI: obo:OPMI_0000302
literal: The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000302
literal: a date when a registration occurs

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000302
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000302
literal: First submitted

AnnotationAssertion
annotation:
  literal: https://www.who.int/ictrp/network/trds/en/
abbreviated IRI: obo:OPMI_0000302
literal: date of registration in primary registry

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000302
literal: date of registration

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000304
literal: The current stage of a clinical study and whether it is or will be open for enrollment

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OPMI_0000304
literal: The recruitment status for the clinical study as a whole, based upon the status of the individual sites. If at least one facility in a multi-site clinical study has an Individual Site Status of "Recruiting," then the Overall Recruitment Status for the study must be "Recruiting."

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000304
literal: Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000304
literal: https://clinicaltrials.gov/ct2/help/glossary/recruitment-status

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000304
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000304
literal: recruitment status

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000304
literal: http://www.icmje.org/recommendations/ http://www.who.int/ictrp/network/trds/en/index.html

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000326
literal: Oliver He, Edison Ong

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000326
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000326
literal: status

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000327
literal: The current stage of a clinical study and whether it is or will be open for enrollment

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000327
literal: Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000327
literal: https://clinicaltrials.gov/ct2/help/glossary/recruitment-status

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000327
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000327
literal: study status

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000364
literal: An annotation property that refers to a code defined by NCIT

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000364
literal: NCIT code

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OPMI_0000365
literal: Combining a drug and device, a biological product and device; a drug and biological product; or a drug, biological product, and device

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000365
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000365
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000365
literal: combinational intervention

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000366
literal: has process quality

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000376
literal: A medical intervention that involves a behavioral process to control, prevent, or treat a behavior problem.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000376
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000376
literal: https://www.understood.org/en/learning-attention-issues/treatments-approaches/educational-strategies/behavior-intervention-plans-what-you-need-to-know

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000376
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
abbreviated IRI: obo:OPMI_0000376
literal: behavioral

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000376
literal: behavioral intervention

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000381
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000381
literal: human subject

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000383
literal: In clinicaltrials.gov, contact information character limits: First Name: 62 characters Last Name: 62 characters Degree: 30 characters Phone: 30 characters Phone Ext: 14 characters Email: 254 characters Citation: https://prsinfo.clinicaltrials.gov/definitions.html#StudyOfficials

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000383
literal: A person who serves as a contact role and has disclosed specified information to be reached. Usually the contact information, such as email and phone number, is provided.,

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000383
literal: Leon, Asiyah, Oliver: Since each contact needs to provide some contact information, we may need to define the contact information.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000383
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000383
literal: https://prsinfo.clinicaltrials.gov/definitions.html#StudyOfficials

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000383
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000383
literal: contact person

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000384
literal: A contact person for each facility participating in a study.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000384
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000384
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000384
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000384
literal: facility contact

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000389
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000389
literal: https://prsinfo.clinicaltrials.gov/definitions.html#StudyOfficials

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000389
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000389
literal: contact of scientific queries

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000390
literal: An investigation agent role that is taken by a human individual

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000390
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000390
literal: human investigator role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000390
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000390
literal: investigator role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000391
literal: a role taken by a person who serves as a contact for some process.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000391
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000391
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000391
literal: contact person role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000393
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000393
literal: https://prsinfo.clinicaltrials.gov/definitions.html#StudyOfficials

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000393
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000393
literal: contact for public queries

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000395
literal: A person to whom questions concerning enrollment at any location of the study can be addressed.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000395
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000395
literal: central contact person

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000395
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000395
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000395
literal: central contact person of study

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000397
literal: information content entity about a contact person

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000397
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000397
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000397
literal: contact person information

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000398
literal: A sponsor role taken by an individual, organization, group or other legal entity which takes responsibility for initiating, managing and/or financing a study. The Primary Sponsor is responsible for ensuring that the trial is properly registered. The Primary Sponsor may or may not be the main funder.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000398
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000398
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000398
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000398
literal: primary sponsor role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000399
literal: A sponsor role taken by an additional individual, organization or another legal person, if any, that has agreed with the primary sponsor to take on responsibilities of sponsorship.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000399
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000399
literal: collaborator role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000399
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000399
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000399
literal: A secondary sponsor may have agreed to: - take on all the responsibilities of sponsorship jointly with the primary sponsor; or - form a group with the Primary Sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or - act as the Primary Sponsor’s legal representative in relation to some or all of the trial sites. by WHO (https://www.who.int/ictrp/network/trds/en/)

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000399
literal: In clinicaltrials.gov, the secondary sponsor role can be taken by a project collaborator (Reference: https://prsinfo.clinicaltrials.gov/trainTrainer/WHO-ICMJE-ClinTrialsgov-Cross-Ref.pdf). However, a secondary sponsor may serve as a collaborator role, but a collaborator may not serve as a secondary sponsor role.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000399
literal: secondary sponsor role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000400
literal: An investigator role taken by an individual who is designated as responsible party by the sponsor

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000400
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000400
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000400
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000400
literal: principal investigator role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000401
literal: An investigator role taken by an individual who both initiates and conducts the study

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000401
literal: Leon Li, Asiyah Lin, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000401
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000401
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000401
literal: sponsor investigator role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000402
literal: An investigation agent role taken by an agent (an individual, organization, group or another legal entity) who provides support to an investigation. The support may include funding, design, implementation, data analysis or reporting. The responsible party is responsible for confirming all collaborators before listing them.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000402
literal: Leon Li, Asiyah Li, Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000402
literal: collaborator role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000402
literal: https://prsinfo.clinicaltrials.gov/definitions.html#Collaborators

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000402
literal: https://www.who.int/ictrp/network/trds/en/

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000402
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000402
literal: A secondary sponsor may serve as a collaborator role. However, a collaborator may not serve as a secondary sponsor role.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000402
literal: investigation collaborator role

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000418
literal: A systematic, scientific investigation that can be either interventional or observational and involves human beings as research subjects. Human subject research can be either medical (clinical) research or non-medical (e.g., social science) research.

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000418
literal: Oliver He

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000418
literal: human investigation

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000418
literal: human study

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000418
literal: https://en.wikipedia.org/wiki/Human_subject_research

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000418
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
abbreviated IRI: obo:OPMI_0000418
literal: human subject study

AnnotationAssertion
abbreviated IRI: obo:PATO_0000047
literal: An organismal quality inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved.

AnnotationAssertion
abbreviated IRI: obo:PATO_0000047
abbreviated IRI: obo:pato.owl

AnnotationAssertion
abbreviated IRI: obo:PATO_0000047
literal: quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0000047
literal: PATO:0000047

AnnotationAssertion
abbreviated IRI: obo:PATO_0000047
IRI: http://purl.oboInOwllibrary.org/oboInOwl/pato#attribute_slim

AnnotationAssertion
abbreviated IRI: obo:PATO_0000047
literal: biological sex

AnnotationAssertion
abbreviated IRI: obo:PATO_0000383
literal: A biological sex quality inhering in an individual or a population that only produces gametes that can be fertilised by male gametes.

AnnotationAssertion
abbreviated IRI: obo:PATO_0000383
abbreviated IRI: obo:pato.owl

AnnotationAssertion
abbreviated IRI: obo:PATO_0000383
literal: quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0000383
literal: PATO:0000383

AnnotationAssertion
abbreviated IRI: obo:PATO_0000383
IRI: http://purl.oboInOwllibrary.org/oboInOwl/pato#mpath_slim

AnnotationAssertion
abbreviated IRI: obo:PATO_0000383
IRI: http://purl.oboInOwllibrary.org/oboInOwl/pato#value_slim

AnnotationAssertion
abbreviated IRI: obo:PATO_0000383
literal: female

AnnotationAssertion
abbreviated IRI: obo:PATO_0000384
literal: A biological sex quality inhering in an individual or a population whose sex organs contain only male gametes.

AnnotationAssertion
abbreviated IRI: obo:PATO_0000384
abbreviated IRI: obo:pato.owl

AnnotationAssertion
abbreviated IRI: obo:PATO_0000384
literal: quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0000384
literal: PATO:0000384

AnnotationAssertion
abbreviated IRI: obo:PATO_0000384
IRI: http://purl.oboInOwllibrary.org/oboInOwl/pato#mpath_slim

AnnotationAssertion
abbreviated IRI: obo:PATO_0000384
IRI: http://purl.oboInOwllibrary.org/oboInOwl/pato#value_slim

AnnotationAssertion
abbreviated IRI: obo:PATO_0000384
literal: male

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: A quality which inheres in an process.

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
abbreviated IRI: obo:pato.owl

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: PATO:0001239

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: PATO:0001240

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: quality of a process

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: quality of occurrent

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: quality of process

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: relational quality of occurrent

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: PATO:0001236

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: See comments of relational quality of a physical entity.

AnnotationAssertion
abbreviated IRI: obo:PATO_0001236
literal: process quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: A quality which inheres in a continuant.

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
abbreviated IRI: obo:pato.owl

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: PATO:0001237

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: PATO:0001238

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: snap:Quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: monadic quality of a continuant

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: multiply inhering quality of a physical entity

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: quality of a continuant

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: quality of a single physical entity

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: quality of an object

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: quality of continuant

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: monadic quality of an object

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: monadic quality of continuant

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: PATO:0001241

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles.

AnnotationAssertion
abbreviated IRI: obo:PATO_0001241
literal: physical object quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0001894
literal: An organismal quality inhering in a bearer by virtue of the bearer's physical expression of sexual characteristics.

AnnotationAssertion
abbreviated IRI: obo:PATO_0001894
abbreviated IRI: obo:pato.owl

AnnotationAssertion
abbreviated IRI: obo:PATO_0001894
literal: quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0001894
literal: PATO:0001894

AnnotationAssertion
abbreviated IRI: obo:PATO_0001894
IRI: http://purl.oboInOwllibrary.org/oboInOwl/pato#attribute_slim

AnnotationAssertion
abbreviated IRI: obo:PATO_0001894
literal: phenotypic sex

AnnotationAssertion
abbreviated IRI: obo:PATO_0001995
literal: A quality that inheres in an entire organism or part of an organism.

AnnotationAssertion
abbreviated IRI: obo:PATO_0001995
abbreviated IRI: obo:pato.owl

AnnotationAssertion
abbreviated IRI: obo:PATO_0001995
literal: quality

AnnotationAssertion
abbreviated IRI: obo:PATO_0001995
literal: PATO:0001995

AnnotationAssertion
abbreviated IRI: obo:PATO_0001995
literal: organismal quality

AnnotationAssertion
abbreviated IRI: obo:PDRO_0000129
abbreviated IRI: obo:IAO_0000123

AnnotationAssertion
abbreviated IRI: obo:PDRO_0000129
literal: An information content entity that describes some relationships between some entities and whose truthfullness is a prerequisite for something.

AnnotationAssertion
abbreviated IRI: obo:PDRO_0000129
literal: Une entité de contenu informationnel qui décrit des relations entre certaines entités et dont la véracité est un prérequis pour quelque chose. @fr

AnnotationAssertion
abbreviated IRI: obo:PDRO_0000129
abbreviated IRI: obo:pdro.owl

AnnotationAssertion
abbreviated IRI: obo:PDRO_0000129
literal: condition

AnnotationAssertion
abbreviated IRI: obo:PDRO_0000129
literal: condition @fr

AnnotationAssertion
abbreviated IRI: obo:RO_0000057
literal: has participant

AnnotationAssertion
abbreviated IRI: obo:RO_0000059
literal: concretizes

AnnotationAssertion
abbreviated IRI: obo:RO_0000087
literal: has role

AnnotationAssertion
abbreviated IRI: obo:RO_0002248
literal: Any portion of roundup 'has active ingredient' some glyphosate

AnnotationAssertion
abbreviated IRI: obo:RO_0002248
literal: A relationship that holds between a substance and a chemical entity, if the chemical entity is part of the substance, and the chemical entity forms the biologically active component of the substance.

AnnotationAssertion
abbreviated IRI: obo:RO_0002248
abbreviated IRI: obo:ro.owl

AnnotationAssertion
abbreviated IRI: obo:RO_0002248
literal: has active substance

AnnotationAssertion
abbreviated IRI: obo:RO_0002248
literal: has active pharmaceutical ingredient

AnnotationAssertion
abbreviated IRI: obo:RO_0002248
literal: has active ingredient

AnnotationAssertion
abbreviated IRI: obo:RO_0002249
literal: active ingredient in

AnnotationAssertion
abbreviated IRI: obo:VO_0000002
literal: a medical intervention that involves in adding vaccine into a host (e.g., human, mouse) in vivo with the intent to invoke an adaptive immune response.

AnnotationAssertion
abbreviated IRI: obo:VO_0000002
abbreviated IRI: obo:oae.owl

AnnotationAssertion
abbreviated IRI: obo:VO_0000002
abbreviated IRI: obo:vo.owl

AnnotationAssertion
abbreviated IRI: obo:VO_0000002
literal: vaccination

AnnotationAssertion
abbreviated IRI: obo:VO_0000002
literal: https://prsinfo.clinicaltrials.gov/definitions.html

AnnotationAssertion
abbreviated IRI: obo:VO_0000427
literal: A vaccine clinical trial that investigates the safety profile of a vaccine in a small group (10-50) of healthy volunteers.

AnnotationAssertion
abbreviated IRI: obo:VO_0000427
literal: YH

AnnotationAssertion
abbreviated IRI: obo:VO_0000427
abbreviated IRI: obo:vo.owl

AnnotationAssertion
abbreviated IRI: obo:VO_0000427
literal: phase 1 vaccine trial

AnnotationAssertion
abbreviated IRI: obo:VO_0000428
literal: A vaccine clinical trial that studies vaccine efficacy with a target population (numbering 50-100). Different dosage levels will also be explored at this stage to determine the optimum dose.

AnnotationAssertion
abbreviated IRI: obo:VO_0000428
literal: YH

AnnotationAssertion
abbreviated IRI: obo:VO_0000428
abbreviated IRI: obo:vo.owl

AnnotationAssertion
abbreviated IRI: obo:VO_0000428
literal: phase 2 vaccine trial

AnnotationAssertion
abbreviated IRI: obo:VO_0000429
literal: A vaccine clinical trial that takes the trial to a large-scale safety and efficacy study in a relevant patient population, usually in excess of 3,000.

AnnotationAssertion
abbreviated IRI: obo:VO_0000429
literal: YH

AnnotationAssertion
abbreviated IRI: obo:VO_0000429
abbreviated IRI: obo:vo.owl

AnnotationAssertion
abbreviated IRI: obo:VO_0000429
literal: phase 3 vaccine trial

AnnotationAssertion
abbreviated IRI: obo:VO_0000430
literal: The final stage of vaccine clinical evaluation. Phase IV occurs after a vaccine or therapy is licensed and is being used by large numbers of people. These studies are not always required or completed.

AnnotationAssertion
abbreviated IRI: obo:VO_0000430
literal: YH

AnnotationAssertion
abbreviated IRI: obo:VO_0000430
abbreviated IRI: obo:vo.owl

AnnotationAssertion
abbreviated IRI: obo:VO_0000430
literal: phase 4 vaccine trial

AnnotationAssertion
abbreviated IRI: obo:VO_0000596
literal: A processual entity by which a vaccine is tested clinically for safety and effectiveness. Clinical trials are conducted in phases. Classically, clinical trials unfold in three phases in order to gather data and information about a vaccine and its performance. This will form the basis of a dossier submitted to regulatory authorities by way of an application for licensure. After a vaccine is licensed and is being used by large numbers of people, a Phase IV study may or may not be taken for vaccine clinical evaluation.

AnnotationAssertion
abbreviated IRI: obo:VO_0000596
literal: Most vaccines against a pathogen (e.g., HIV) are not tested by vaccinating people and then deliberately exposing them to virulent pathogen (e.g., HIV). This strategy is never for a vaccine against a disease as serious as HIV. The best way to determine if a vaccine is effective is to test it in a randomized, controlled, double-blind clinical trial. This type of trial is often referred to as the gold standard in medical research and provides the strongest evidence for the efficacy of a vaccine.

AnnotationAssertion
abbreviated IRI: obo:VO_0000596
literal: YH

AnnotationAssertion
abbreviated IRI: obo:VO_0000596
abbreviated IRI: obo:vo.owl

AnnotationAssertion
abbreviated IRI: obo:VO_0000596
literal: vaccine clinical trial

AnnotationAssertion
abbreviated IRI: obo:omrse.owl
literal: The Ontology of Medically Related Social Entities

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/ncbitaxon#has_rank
literal: A metadata relation between a class and its taxonomic rank (eg species, family)

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/ncbitaxon#has_rank
literal: ncbi_taxonomy

AnnotationAssertion
IRI: http://purl.obolibrary.org/obo/ncbitaxon#has_rank
literal: has_rank

AnnotationAssertion
abbreviated IRI: dc:description
literal: Description may include but is not limited to: an abstract, table of contents, reference to a graphical representation of content or a free-text account of the content.

AnnotationAssertion
abbreviated IRI: dc:description
literal: An account of the content of the resource.

AnnotationAssertion
abbreviated IRI: dc:description
abbreviated IRI: dc:

AnnotationAssertion
abbreviated IRI: dc:description
literal: Description

AnnotationAssertion
abbreviated IRI: dc:description
literal: Description

AnnotationAssertion
abbreviated IRI: dc:source
literal: The present resource may be derived from the Source resource in whole or in part. Recommended best practice is to reference the resource by means of a string or number conforming to a formal identification system.

AnnotationAssertion
abbreviated IRI: dc:source
literal: A reference to a resource from which the present resource is derived.

AnnotationAssertion
abbreviated IRI: dc:source
abbreviated IRI: dc:

AnnotationAssertion
abbreviated IRI: dc:source
literal: Source

AnnotationAssertion
abbreviated IRI: dc:source
literal: Source

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
IRI: http://purl.org/net/OCRe/research.owl#Case_control_study
literal: Group of individuals with specific characteristics (for example, conditions or exposures) compared to group(s) with different characteristics, but otherwise similar.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
IRI: http://purl.org/net/OCRe/research.owl#Case_crossover_study
literal: Characteristics of case immediately prior to disease onset (sometimes called the hazard period) compared to characteristics of same case at a prior time (that is, control period).

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
IRI: http://purl.org/net/OCRe/research.owl#Cohort_study
literal: Group of individuals, initially defined and composed, with common characteristics (for example, condition, birth year), who are examined or traced over a given time period.

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
IRI: http://purl.org/net/OCRe/research.owl#Parallel_group_study
literal: Participants are assigned to one of two or more groups in parallel for the duration of the study

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
IRI: http://purl.org/net/OCRe/study_design.owl#Crossover_study
literal: Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study

AnnotationAssertion
annotation:
  literal: https://prsinfo.clinicaltrials.gov/definitions.html
IRI: http://purl.org/net/OCRe/study_design.owl#Single_group_study
literal: Clinical trials with a single arm

AnnotationAssertion
abbreviated IRI: oboInOwl:hasAlternativeId
literal: has_alternative_id

AnnotationAssertion
abbreviated IRI: oboInOwl:hasDbXref
literal: database_cross_reference

AnnotationAssertion
abbreviated IRI: oboInOwl:hasExactSynonym
literal: A property representing a fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software.

AnnotationAssertion
abbreviated IRI: oboInOwl:hasExactSynonym
literal: Fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software.

AnnotationAssertion
abbreviated IRI: oboInOwl:hasExactSynonym
literal: FULL_SYN

AnnotationAssertion
abbreviated IRI: oboInOwl:hasExactSynonym
literal: Synonym with Source Data

AnnotationAssertion
abbreviated IRI: oboInOwl:hasExactSynonym
literal: has exact synonym

AnnotationAssertion
abbreviated IRI: oboInOwl:hasExactSynonym
literal: has_exact_synonym

AnnotationAssertion
abbreviated IRI: oboInOwl:hasNarrowSynonym
literal: has_narrow_synonym

AnnotationAssertion
abbreviated IRI: oboInOwl:hasOBONamespace
literal: has_obo_namespace

AnnotationAssertion
abbreviated IRI: oboInOwl:hasRelatedSynonym
literal: has_related_synonym

AnnotationAssertion
abbreviated IRI: oboInOwl:inSubset
literal: An association that connects the concept defining a particular terminology subset with concepts that belong to this subset.

AnnotationAssertion
abbreviated IRI: oboInOwl:inSubset
literal: Used to associate the concept defining a particular terminology subset with concepts that belong to this subset.

AnnotationAssertion
abbreviated IRI: oboInOwl:inSubset
literal: Concept_In_Subset

AnnotationAssertion
abbreviated IRI: oboInOwl:inSubset
literal: in subset

AnnotationAssertion
abbreviated IRI: oboInOwl:inSubset
literal: in_subset

AnnotationAssertion
abbreviated IRI: oboInOwl:shorthand
literal: shorthand

AnnotationAssertion
abbreviated IRI: rdfs:label
literal: label

AnnotationAssertion
abbreviated IRI: rdfs:label
literal: label

AnnotationAssertion
abbreviated IRI: rdfs:label
literal: label

AnnotationAssertion
abbreviated IRI: rdfs:subClassOf
abbreviated IRI: obo:gaz.owl

AnnotationAssertion
abbreviated IRI: rdfs:subClassOf
abbreviated IRI: obo:opmi.owl

AnnotationAssertion
IRI: obo:CTO_0000021
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Korean Clinical Research Information Service (CRIS). The format for the registry number is “KCT” followed by a 7-digit number, e.g., KCT0004537.

AnnotationAssertion
IRI: obo:CTO_0000021
literal: CRIS identifier

AnnotationAssertion
IRI: obo:CTO_0000021
literal: Korean clinical trial registry identifier

AnnotationAssertion
IRI: obo:CTO_0000021
literal: http://cris.nih.go.kr/cris/en/use_guide/cris_introduce.jsp

AnnotationAssertion
IRI: obo:CTO_0000027
literal: A centrally registered identifier that is assigned for a specific clinical trial registered in the Sri Lanka clinical trials registry (SLCTR ). The format for the registry number is “SLCTR /” followed by a 4-digit number, followed by a slash, followed a 3-digit number, e.g., SLCTR/2020/010

AnnotationAssertion
IRI: obo:CTO_0000027
literal: SLCTR identifier

AnnotationAssertion
IRI: obo:CTO_0000027
literal: Sri Lanka clinical trials registry identifier

AnnotationAssertion
IRI: obo:CTO_0000027
literal: https://slctr.lk/

AnnotationAssertion
IRI: obo:CTO_0000029
literal: The jRTC (Japan Registry of Clinical Trials) clinical trial registry is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
IRI: obo:CTO_0000029
literal: Japan Registry of Clinical Trials

AnnotationAssertion
IRI: obo:CTO_0000029
literal: jRTC

AnnotationAssertion
IRI: obo:CTO_0000029
literal: jRTC clinical trials register

AnnotationAssertion
IRI: obo:CTO_0000029
literal: https://jrct.niph.go.jp/

AnnotationAssertion
IRI: obo:CTO_0000029
literal: https://rctportal.niph.go.jp/en/

AnnotationAssertion
IRI: obo:CTO_0000042
literal: The international standard randomised controlled trial register is a primary clinical trial registry recognised by WHO and ICMJE that enables the registration of clinical trials.

AnnotationAssertion
IRI: obo:CTO_0000042
literal: ISRCTN

AnnotationAssertion
IRI: obo:CTO_0000042
literal: International standard randomised controlled trial register

AnnotationAssertion
IRI: obo:CTO_0000042
literal: http://www.isrctn.com/

AnnotationAssertion
abbreviated IRI: obo:obi.owl

AnnotationAssertion
abbreviated IRI: obo:omrse.owl

AnnotationPropertyRange
abbreviated IRI: xsd:boolean

AnnotationPropertyRange
abbreviated IRI: xsd:anyURI

AnnotationPropertyRange
abbreviated IRI: xsd:string

AnnotationPropertyRange
abbreviated IRI: obo:NCIT_Semantic_Type-enum

AnnotationPropertyRange
abbreviated IRI: xsd:string

AnnotationPropertyRange
abbreviated IRI: xsd:string

AnnotationPropertyRange
abbreviated IRI: xsd:string

AnnotationPropertyRange
abbreviated IRI: xsd:string

AnnotationPropertyRange
abbreviated IRI: obo:NCIT_Contributing_Source-enum

AnnotationPropertyRange
abbreviated IRI: obo:NCIT_textArea

AnnotationPropertyRange
abbreviated IRI: xsd:string

AnnotationPropertyRange
abbreviated IRI: xsd:string

AnnotationPropertyRange
abbreviated IRI: obo:NCIT_textArea

AnnotationPropertyRange
abbreviated IRI: xsd:string